



#### **Market snapshot**



Equities - India	Close	Chg.%	CYTD.%					
Sensex	81,119	-0.7	3.8					
Nifty-50	24,719	-0.7	4.5					
Nifty-M 100	58,227	-0.4	1.8					
<b>Equities-Global</b>	Close	Chg .%	CYTD.%					
S&P 500	5,977	-1.1	1.6					
Nasdaq	19,407	-1.3	0.5					
FTSE 100	8,851	-0.4	8.3					
DAX	23,516	-1.1	18.1					
Hang Seng	8,655	-0.9	18.7					
Nikkei 225	37,834	-0.9	-5.2					
Commodities	Close	Chg .%	CYTD.%					
Brent (US\$/Bbl)	71	0.0	-4.4					
Gold (\$/OZ)	3,415	0.9	30.1					
Cu (US\$/MT)	9,645	-1.5	11.5					
Almn (US\$/MT)	2,503	-0.7	-0.9					
Currency	Close	Chg .%	CYTD.%					
USD/INR	86.1	0.6	0.6					
USD/EUR	1.2	-0.6	11.2					
USD/JPY	144.2	0.5	-8.2					
YIELD (%)	Close	1MChg	CYTD chg					
10 Yrs G-Sec	6.4	0.02	-0.4					
10 Yrs AAA Corp	7.0	0.00	-0.3					
Flows (USD b)	13-Jun	MTD	CYTD					
FIIs	-0.1	-0.20	-10.6					
DIIs	0.35	5.51	38.2					
Volumes (INRb)	13-Jun	MTD*	YTD*					
Cash	1,120	1252	1073					
F&O	99,622	2,04,964	2,09,002					

Note: Flows, MTD includes provisional numbers.

### Today's top research idea

# Retail: Value retail delivers broad-based gains amid competitive headwinds

- ❖ Value fashion retailers continued to outperform premium and branded apparel retailers during FY25, driven by structural factors such as (i) rising aspirations in tier 2/3/4 cities, (ii) a continued shift from unorganized to organized retailers, (iii) deeper private label penetration and more options for consumers under one roof, and (iv) accelerated store expansion.
- ❖ In FY25, the four listed value retailers —(VMM, V-Mart, Style Bazaar, V2 Retail) —posted combined revenue growth of 24%, supported by 16% retail area addition and healthy double-digit same-store sales growth (SSSG). V2 Retail (V2REL) stood out with ~60% store area additions and ~29% SSSG (vs. ~12-13% for other listed peers).
- Margin profile of value retailers improved, as FY25 blended gross margins for listed companies expanded ~50bp YoY to 29% (~150bp improvement in 4Q), reflecting an improved product mix, higher MRP sales and procurement efficiencies.
- ❖ Vishal Mega Mart (VMM) saw the highest gross margin expansion of ~80bp YoY in FY25 (~180bp YoY in 4Q), driven by rising share of private-label brands.
- Pre-IND AS EBITDA margin expanded by ~180bp YoY to 8.2%, the highest in recent years, driven by improved sourcing (private label mix, vendor consolidation), operating leverage benefits, and better inventory turns.




#### Research covered

Cos/Sector	Key Highlights
Retail	Value retail delivers broad-based gains amid competitive headwinds
UTI AMC	Strong fund performance to revive market share
<b>Galaxy Surfactants</b>	Scaling with strategic clarity and focus
Financials - Banks	Credit growth further decelerated to 8.97%; Deposit growth now stands ~100bp higher than credit growth

## П


#### Chart of the Day: Retail (Value retail delivers broad-based gains amid competitive headwinds)

#### V2 Retail dominate FY25 SSSG performance



Source: Company, MOFSL





Source: Company, MOFSL

#### Research Team (Gautam.Duggad@MotilalOswal.com)

<sup>\*</sup>Average





### In the news today



Kindly click on textbox for the detailed news link

1

Tata Steel aims 15 MT production via recycling in 10-15 years: CEO T V Narendran

The steel major aims to scale up its steel making capacity to 40 MT by 2030 in India

2

Adani's Haifa Port operating 'normally' amid Iran's retaliatory missile strikes on Israeli cities

Israel attacked Iran early Friday targeting its nuclear, missile and military infrastructure. Iran later launched retaliatory strikes on Israel.

3

Hero FinCorp garners ₹260 cr from investors in pre-IPO round

This fund mobilisation led to a reduction in fresh issue size to ₹1,840 crore from ₹2,100 crore planned earlier

4

Wonderla Holidays expands into retreats, launches The Isle resort

Developed with an investment of ₹39 crore, The Isle is priced from ₹10,000 onwards and is part of a larger expansion plan

5

Joint fact-finding report confirms ₹220.52 crore inventory overstatement at Ramkrishna Forgings

Adverse impact close to 7% on net worth of the company seen

6

PAG backed Manjushree
Technopack may spend \$150180m to acquire 4-5 assets as
packaging sector undergoes
consolidation

The sector, which is at the cusp pf consolidation, has shown substantial growth potential

7

Near-term volumes and margins for Bosch likely to remain under pressure

While there are medium- to long-term triggers, especially on the margin front, the Street is cautious on the near-term outlook


16 June 2025

\_ ر



### **Retail**

SSSG remained strong across value retailers, driven by resilient tier 2/3 demand, festive tailwinds, and improved private label execution. Mgmt. guides for high single digit SSSG in FY26, despite a strong base.





#### Value retail delivers broad-based gains amid competitive headwinds

- Value fashion retailers continued to outperform premium and branded apparel retailers during FY25, driven by structural factors such as (i) rising aspirations in tier 2/3/4 cities, (ii) a continued shift from unorganized to organized retailers, (iii) deeper private label penetration and more options for consumers under one roof, and (iv) accelerated store expansion. In FY25, the four listed value retailers (VMM, V-Mart, Style Bazaar, V2 Retail) —posted combined revenue growth of 24%, supported by 16% retail area addition and healthy double-digit same-store sales growth (SSSG). V2 Retail (V2REL) stood out with ~60% store area additions and ~29% SSSG (vs. ~12-13% for other listed peers). In 4QFY25, their combined revenue rose 28% YoY, supported by ~16% YoY retail area addition and ~11% YoY growth in monthly sales per sqft (SPSF) to ~INR700 in 4Q (up 11% to INR754 in FY25). Growth was largely led by volume, as the average transaction value (ATV) for value fashion retailers was steady (down 2% YoY to INR935 in FY25 and up 1% YoY to INR929 in 4QFY25).
- Margin profile of value retailers improved, as FY25 blended gross margins for listed companies expanded ~50bp YoY to 29% (~150bp improvement in 4Q), reflecting an improved product mix, higher MRP sales and procurement efficiencies. Vishal Mega Mart (VMM) saw the highest gross margin expansion of ~80bp YoY in FY25 (~180bp YoY in 4Q), driven by rising share of private-label brands. Pre-IND AS EBITDA margin expanded by ~180bp YoY to 8.2%, the highest in recent years, driven by improved sourcing (private label mix, vendor consolidation), operating leverage benefits, and better inventory turns. In 4QFY25, pre-INDAS EBITDA margins expanded ~230bp YoY to 6.1%, despite a 40% YoY increase in employee costs. V-Mart accounted for ~50% of the sectoral margin expansion, posting a sharp rebound to 4% (vs. near-zero in FY24), driven by lower losses in online venture (LimeRoad) and improvement in SSSG.
- While gains were broad-based, rising cost intensity from scale-up (warehousing, corporate overheads) capped further margin upside. Steady expansion will require backend productivity gains and improvement in SPSF of new stores.
- Working capital and cash flow metrics also improved meaningfully, supported by enhanced backend controls, tighter assortment planning, and faster full-price sell-through. Average inventory days remained stable at 83 (vs. 81 YoY), though the quality of inventory improved significantly, with a sharp reduction in aged stock. Working capital intensity largely remained flat at 23 days (vs. 22 YoY), aided by vendor-led sourcing and shorter procurement cycles, despite continued retail expansion. Pre-IND AS operating cash flows improved sharply to INR10b (vs. INR4b YoY). Despite aggressive store expansion, free cash flow also improved to INR4b (vs. FCF outflows in past several years). However, this recovery was skewed, with VMM accounting for ~60% of sector revenue and the majority of profit and cash generation.
- Store expansion remained aggressive as companies added ~16% retail area YoY in FY25, predominantly in tier 2/3/4 markets. New store performance improved as reflected in rising SPSF metrics, though most of them remain in the early ramp-up phase. Rental inflation remained contained for value retailers; however, limited availability of quality real estate in priority clusters necessitated increased adoption of build-to-suit formats. While new store additions exerted near-term margin pressure, retailers expect operating leverage to kick in when stores mature. FY26 guidance implies 15-20% YoY area growth, with a focus on RoCE and payback benchmarks, ensuring capital-efficient expansion amid intensifying competition.



#### Value retail industry performance over FY20-25

P&L (INR m)	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	82,848	64,933	84,350	116,777	138,352	171,984
% YoY Growth	45	-22	30	38	18	24
Raw Material cost	59,098	46,315	59,222	82,528	97,631	120,515
Gross Profit	23,750	18,619	25,128	34,248	40,721	51,469
Gross Margin (%)	28.7	28.7	29.8	29.3	29.4	29.9
Employee Costs	6,070	4,920	6,213	8,375	9,689	12,581
Other Expenses	7,742	5,335	7,544	11,176	13,570	15,396
Total Expenses	13,812	10,255	13,757	19,551	23,259	27,977
EBITDA	9,938	8,364	11,371	14,697	17,462	23,492
% YoY Growth	109.2	-15.8	36.0	29.3	18.8	34.5
EBITDA margin (%)	12.0	12.9	13.5	12.6	12.6	13.7
IND AS Adj (Rent)			6,579	7,755	8,537	9,312
Pre-IND AS EBITDA			4,792	6,942	8,925	14,180
% YoY Growth				44.9	28.6	<b>58.9</b>
EBITDA margin (%)			5.7	5.9	6.5	8.2
Depreciation and amortization	7,797	3,641	4,020	4,669	8,854	10,179
EBIT	2,141	4,723	7,352	10,029	8,608	13,313
EBIT margin (%)	2.6	7.3	8.7	8.6	6.2	7.7
Finance Costs	2,689	1,732	1,990	2,490	3,815	4,209
Other income	684	871	681	561	709	850
Exceptional item	-	_	-	-	-	-349
Profit before Tax	136	3,862	6,042	8,100	5,503	10,303
Tax	2,348	545	374	942	1,359	2,455
Tax rate (%)	1730.8	14.1	6.2	11.6	24.7	23.8
Profit after Tax	-2,212	3,317	5,668	7,158	4,144	7,848
% YoY Growth			71	26	-42	89
Operational Metrics	FY25	FY25	FY25	FY25	FY25	FY25
Stores	710	886	1,088	1,217	1,334	1,596
Area	10	12	14	16	18	20
Metrics on per sqft						
Revenue	714	504	535	634	681	754
Cost of Retailing (CoR)	119	80	87	106	115	123
Inventory	2,085	1,583	1,679	1,802	1,744	1,905
Operational Highlights (Ex-VMM)						
Bills Cut	30.9	23.6	31.0	42.3	51.8	69.3
ATV	970	865	917	968	950	935

Source: MOFSL, Company

Buy



### **UTI AMC**

 BSE SENSEX
 S&P CNX

 81,119
 24,719

**U** 

#### Stock Info

Bloomberg	UTIAM IN
Equity Shares (m)	128
M.Cap.(INRb)/(USDb)	157.4 / 1.8
52-Week Range (INR)	1408 / 905
1, 6, 12 Rel. Per (%)	16/-9/19
12M Avg Val (INR M)	335
Free float (%)	100.0

#### Financials Snapshot (INR b)


Y/E March		20265	2027E
		2026E	
AAUM	3,363	3,888	4,576
MF Yield (bps)	34.2	33.2	32.2
Rev from Ops	14.5	16.2	18.5
Core PAT	4.9	5.9	7.1
PAT	8.1	9.1	10.5
PAT (bps as AAUM)	24	23	23
Core EPS	39	46	56
EPS	64	71	82
EPS Grw. (%)	1	12	16
BVPS	405	427	452
RoE (%)	16	17	19
Div. Payout (%)	74	70	70
Valuations			
Mcap/AUM (%)	4.6	4.0	3.4
P/E (x)	19.2	17.2	14.9
P/BV (x)	3.0	2.9	2.7
Div. Yield (%)	3.9	4.0	4.7
	•	•	

#### **Shareholding Pattern (%)**

As On	Mar-25	Dec-24	Mar-24
Promoter	0.0	0.0	0.0
DII	59.7	59.3	60.9
FII	7.9	7.9	6.0
Others	32.4	32.9	33.1

FII includes depository receipts

#### **Stock Performance (one-year)**



CMP: INR1,230 TP: INR1,550 (+26%)

#### Strong fund performance to revive market share

SIPs continue to scale up; least re-rated stock in the universe

- UTI AMC's fund performance over the past five months has improved considerably, with an average of ~70% equity AUM appearing in Q1 and Q2 on a one-year return basis in May'25 vs an average of 25% in the preceding 12 months. This, we believe, can drive equity market share gains, which have been stable at 3.9% over the past seven months.
- Recent product launches (Quant Fund launched in Q4FY25 and Multi-Cap Fund in Apr'25) are likely to support equity inflows. Ongoing traction in hybrid funds and the rollout of smart beta and thematic offerings further enhance UTI AMC's positioning across investor segments.
- UTI AMC's SIP AUM grew 22% YoY to INR375.9b, supported by increased investor engagement through MFDs and direct platforms. Despite weaker markets, SIP inflows in FY25 rose 23% YoY to INR83.3b. Notably, 47.9% of equity/hybrid gross sales were mobilized through digital platforms in Q4FY25, reflecting the success of platform integration and marketing automation.
- UTI AMC continues to deepen penetration in B30 cities, with 22% of monthly average AUM in Mar'25 originating from these regions—outperforming the industry average of ~18%. The company added 68 branches in Tier-2 and Tier-3 locations during FY25, driving incremental folio growth (0.9m net folio additions in FY25).
- Overall yields stood at ~34bp in Q4FY25. While equity and hybrid funds earned ~75bp, a growing share of passive flows (ETF/index funds at 5–6bp yield) is expected to lead to a slight yield contraction (1-2bp), partially cushioned by distributor commission rationalization.
- We expect UTI AMC to report AUM/Revenue/Core PAT CAGR of 17%/13%/20% over FY25-27. Sustained strong performance has been a key re-rating driver for AMC stocks. UTI AMC's discount to other players has widened over the past few months. We reiterate our BUY rating on UTI AMC with a one-year TP of INR1,550, based on 19x FY27E EPS (28x Core EPS).

## Fund performance sees significant improvement based on one-year returns

- As a % of Monthly Average AUM (MAUM): The share of AUM ranked in the top quartile (one-year returns) rose sharply to 48% in May'25, up from just 12% in May'21. Conversely, the proportion of AUM in the top quartile based on three-year returns declined to 8% from 38% over the same period.
- Based on the number of schemes: The number of schemes ranked in the top quartile (one-year return) improved significantly to 6 in May'25 from 2 in May'21. For three-year returns, the number of top-quartile schemes rose modestly to 3 from 2 over the same period, indicating an overall positive trend in performance.




#### Equity segment: Better fund performance and new product launches being key growth drivers

- Equity QAAUM grew 7.2% YoY to INR908.6b, with net sales turning positive at INR13b in 4QFY25, compared to net outflows of INR13.4b in 4QFY24. However, on a yearly basis, net outflow stood at INR19.2b, reducing YoY from INR56.7b in FY24.
- The equity market share declined to 3.1% in 4QFY25 vs 3.7% in 4QFY24 and 3.2% in 3QFY25. However, with improving fund performance (57% of equity AUM in the top two quartiles over the past year), the launch of new funds (BAF launched in Jul'23, multi-cap in FY25, Quant Fund in 4QFY25) and the scaling up of SIPs through digital partnerships are expected to support growth in equity AUM, thus leading to higher market share for UTI AMC.


#### QAAUM mix (%)

#### **Equity AUM continues to trend upwards**




Source: MOFSL, Company

#### Market share has stabilized over the last few months despite the fall from the peak




Source: MOFSL, Company



Source: MOFSL, Company

Buy





## **Galaxy Surfactants**

**BSE SENSEX S&P CNX** 81,119 24,719

CMP: INR2,381 TP: INR3,180 (+34%)



**GALSURF IN** 

3370 / 2021

7/-14/-16

35

71

29.1

84.4 / 1

#### Scaling with strategic clarity and focus

We attended Galaxy Surfactants' (GALSURF) capital market day in Mumbai on 13<sup>th</sup> Jun'25. Below are the key highlights of the event:

#### A decade of strong foundations and profitable growth

- Over the past 10 years, GALSURF has demonstrated its ability to scale profitably while navigating cyclical and regional challenges. During FY15-25, the company doubled its total volumes, supported by deeper market penetration and category expansion, particularly in rinse-off personal care and home care products. During this same period, EBITDA tripled, driven by operational efficiencies, product mix enhancement, and innovation. PAT grew 5x, reflecting sharp execution and cost control.
- GALSURF achieved an average RoCE of 22%, a testament to disciplined capital allocation and return-oriented investment. EBITDA/kg also doubled, highlighting the company's ability to extract more value per unit of product. Despite macroeconomic headwinds in the early part of this decade, including inflation and demand volatility, the company maintained strong profitability, setting a firm base for future expansion.

#### Financials Snapshot (INR b)

Stock Info

Bloomberg
Equity Shares (m)

M.Cap.(INRb)/(USDb)

52-Week Range (INR)

1, 6, 12 Rel. Per (%)

12M Avg Val (INR M)

Free float (%)

i illaliciais Silap	Tilialiciais Shapshot (livit b)											
Y/E March	FY25	FY26E	FY27E									
Sales	42.2	48.0	55.0									
EBITDA	4.8	5.2	5.8									
PAT	3.0	3.3	3.8									
EPS (INR)	86	93	106									
EPS Gr. (%)	1.1	8.4	13.8									
BV/Sh.(INR)	666	736	815									
Ratios												
Net D:E	-0.0	-0.1	-0.1									
RoE (%)	13.4	13.3	13.7									
RoCE (%)	13.1	13.0	13.5									
Payout (%)	25.6	25.6	25.6									
Valuations												
P/E (x)	27.6	25.5	22.4									
P/BV (x)	3.6	3.2	2.9									
EV/EBITDA (x)	17.2	15.7	13.9									
Div. Yield (%)	0.9	1.0	1.1									
FCF Yield (%)	2.4	2.6	2.9									

#### Shareholding pattern (%)


As On	Mar-25	Dec-24	Mar-24
Promoter	70.9	70.9	70.9
DII	13.0	13.0	12.7
FII	4.1	4.2	3.8
Others	12.1	11.9	12.6

FII Includes depository receipts

#### Vision 2030: Forging forward

- Looking ahead to 2030, GALSURF has outlined an ambitious but well-structured growth roadmap. Over the next five years, the company plans to **double its volumes and grow EBITDA by 2.5x**, while sustaining a **RoCE greater than 22%**. Its key internal goal is to achieve an **EBITDA/kg of INR25** by FY30. This growth will be driven by a mix of organic, portfolio-led, and ecosystem-driven initiatives.
- The company expects **50% of incremental EBITDA** to come from **organic growth** in rinse-off categories such as hair care, oral care, and body wash—segments where GALSURF already has a strong presence. Around **30% of EBITDA growth** is projected to come from **new product portfolios**, particularly in high-value, leave-on categories like moisturizers, sunscreens, and serums. The remaining **20% will be driven by new avenues**, including strategic partnerships, collaborations, and expansion into wellness and beauty-focused solutions.
- GALSURF's 2030 vision is centered on defending and deepening its leadership in India and AMET markets, winning new customers and applications in the Americas, and making focused inroads into specialties in the European Union. This will be enabled through what the management calls the '3D' approach—Development, Digitalization, and Distribution—backed by investments in innovation, technology, and talent.

#### Stock performance (one-year)





#### Riding on global trends: A shifting industry landscape

- GALSURF operates in an ingredients market with a total addressable value of USD42b, of which USD30b is directly relevant to its surfactants and specialty chemicals portfolio. The total global ingredient volume stands at 15mmt, with GALSURF's focus market comprising 10mmt, of which 9mmt is surfactants and 1mmt includes preservatives, UV protection, and emollients.
- The global home care ingredients market is estimated at USD26b, dominated by surfactants (72% share). Evolving consumer preferences in developed markets are driving demand for unit dose detergents (pods), eco-friendly formats, and low-residue formulations due to stricter regulatory norms (e.g., 1,4-Dioxane limits). Meanwhile, in developing regions, there is a shift from bar and powder-based formats to liquids and premium detergents, opening new avenues for GALSURF.
- In the personal and beauty care segment, which is a USD475b market globally, GALSURF sees immense opportunities, especially in skincare, sun care, and clean beauty. The ingredients market within this segment is USD16b in value and 4mmt in volume. With a 5.7% CAGR, it is expected to outpace other segments, led by consumer shifts towards natural, multifunctional, and sustainable solutions.

**Exhibit 1: Performance in the previous decade** 

CAGR	FY15-25	FY15-20	FY20-25
	TV.		7
<b>Total Volume</b>	5%	8%	3%
	A.		k.
EBITDA	10%	14%	6%
$\rightarrow$			
EBITDA/MT	5%	6%	4%
	- Y		V
PAT	16%	28%	6%
	-A-	1	<b>N</b>
AVG. ROCE	22%	23%	20%

Source: Company, MOFSL



#### Valuation and view

- We believe that going forward, volume growth will be driven by the company's steady focus on R&D (with an annual expenditure of INR400-500m), increased wallet share from its existing customers, and acquisition of new customers. Margin is also likely to expand gradually with an increase in the volume of premium specialty products.
- We estimate a volume CAGR of 6% over FY25-27, driven by improving volumes in the Specialty Care segment across developed markets and a recovery in demand, albeit gradual, from rural and urban markets in India. The stock is currently trading at ~22x FY27E EPS of INR106 and ~14x FY27E EV/EBITDA. We value the company at 30x FY27E EPS to arrive at a TP of INR3,180. We reiterate our BUY rating on the stock.



### **Financials: Banks**


## Credit growth further decelerated to 8.97%; Deposit growth now stands ~100bp higher than credit growth

- Systemic credit growth has declined sharply to 8.97% YoY for the fortnight ended 30<sup>th</sup> May'25, lowest amongst the past 3 years (previous fortnight at 9.8% YoY).
- Systemic Deposit growth has stood at 9.9% YoY (previous fortnight print at 10% YoY).
- Deposit growth now stands ~100bp higher than credit growth after trailing behind significantly over the recent years which resulted in significant concerns and regulatory watch on Credit-Deposit ratio as well.
- Outstanding LDR for the system has thus moderated to 78.9% (previous fortnight at 79.6%). Incremental LDR over the year has also declined sharply to 72.2% vs 98.8% a year back.
- We had published our note on 23<sup>rd</sup> May'25 on Channels checks titled "**Ground Zero: Channel Check Boots, Branches, and Beyond**" (<u>Link</u>) wherein we highlighted the ongoing slackness in credit demand and sharp decline in retail enquiries alongside a cautious stance followed by the lenders.
- The deceleration in credit growth has been sharp over the past 1 year, as lenders are prioritizing asset quality amid higher delinquencies in unsecured retail, MFI while continuously tightening the underwriting standards. We currently estimate credit growth to remain modest at 11.5% YoY for FY26E and recovering thereafter to 13% in FY27E.



### **Story in Charts**


#### Credit growth declined to 8.97% %, while deposits growth steady at 9.89%



Deposits growth at 9.89% higher than credit growth at 8.97%

Source: MOFSL, RBI


#### Differential in credit and deposits growth stood at -0.9%



Differential in credit vs deposits growth lowest in past 3 years at -0.9%

Source: MOFSL, RBI

#### Outstanding LDR decreased to 78.9%, while incremental LDR decreased sharply to 72.2%



Incremental LDR declined sharply to 72.2% (lowest in past 3 years), while LDR declined to 78.9%

Source: MOFSL, RBI







# Ashok Leyland's Strategy To Absorb Regulatory Costs, Adapting MHCV Designs; Dr. N. Kamakodi, CEO

- AC Cabins Mandatory from June 2025: All new trucks to be AC-equipped from June 8, 2025; old inventory can still be sold.
- No Margin Hit from AC Cost: Price hike of 1–1.5% to be passed to customers; minimal impact on margins.
- MHCV Growth Outlook Positive: Industry expected to grow mid-to-high single digits in FY26; ASHLEY aims to outperform.
- Bus Segment Strength & Macro Tailwinds: Strong demand from STUs, schools, staff transport; fleet utilization up, with recovery seen from Q3 onwards.



# DCM Shriram: Interest cost will become negligible post debt repayment; Amit Agarwal, ED & Group CFO

- Acquires Hindusthan Specialty Chemicals for ₹375cr, enabling downstream integration from its ECH business and entry into high-value advanced materials.
- Target's debt to be fully repaid, sharply reducing interest outgo and aiding turnaround of the loss-making entity within a year.
- DCM to supply ECH, pushing utilization from ~65% to 85–90% in a year, with focus on swift profitability.
- Plans to triple epoxy resin capacity and grow derivatives 4–5x in 3 years, with meaningful impact on revenue and margins.



# Capri Global Capital: Gold loans account for 35% of AUM and won't exceed 40%; Rajesh Sharma, Managing Director

- Strong demand (~₹4,300cr) from marquee investors incl. BlackRock, Quant MF, HDFC Life, and Tata AIF.
- AUM target of ₹50,000cr in 3 years (30% CAGR); to add 150–200 branches to its 1,100-branch network in FY26.
- Gold loans form 35% of AUM; GNPA at 1.5%, NNPA under 1% as of Mar'25, maintaining strong asset quality.
- ₹90cr annual tech spend; recent fundraise + expected rating upgrade likely to cut CoF by 50–60bps.



## City Union Bank: Have changed gold loan portfolio to fixed rate vs earlier floating rate products; Dr. N. Kamakodi, CEO

- Bank maintains mid-teen loan growth guidance for FY26; recent CRR cut adds marginal support.
- 25% of book in gold loans now on fixed rates, aiding NIM stability (~3.5–3.6%).
- 60–70% of gold loans <₹2.5L; not raising LTV to 85% yet, watching gold prices closely.
- Gradual build-up; target is 5% of book over 3–5 yrs. Asset quality strong; ROA expected at ~1.5%.







Company   Reco			C1.10		0/11-11		EDC /INIT			<u> </u>	(0/)	5.1-	- ()	5/-	<b>1</b> (-2)		(0/)
Part	Company	Pace			•		•	•			• •		• •		• •		• •
Marchis   Marc		Reco	(IIVK)	(IIVK)	Downside	F125E	r120E	r12/E	г124	F125E	F12bE	F125E	F1ZbE	F1Z5E	F12bE	FTZ5E	r120E
Apollo Proyers		Neutral	1003	1075	7	48.2	50.2	50 7	-2 7	15	18.6	20 g	100	2.5	2 2	12 1	12.5
Annicon	-																
Salpi Number   Neutro   2648   2688   3   2995   301   3704   1184   1092   1252   281   256   74   618   275	·	•															
Baltenbanders	•	•															
Banatrogreg   Neutral   3169   2958   76   6824   7979   9244   8109   8169																	
Post																	
Craftsman																	
Carbinam Auto   Neutral   Sado   Alta   Sado   Sa																	
Figuration   Fig		•															
Part																	
First Number   Firs																	
Exist		•															
Harpon Forgings																	
Herno Motor																	
Mam	,	•															
Memory   M		•															
CIC Automotive   Buy	•	•															
Maruti Suzuki   Buy		•															
MRF   Seli																	
Saminardinan		•															
Motherson   Moth		Seii	13/542	105295	-23	4,408.7	4,679.8	5,264.8	-11./	6.1	12.5	31.2	29.4	3.2	2.9	10.6	10.2
Some BLW Precis.   Neutral   Solit		Buy	154	175	14	5.3	5.8	7.3	44.3	7.6	27.6	28.8	26.8	3.1	2.9	12.5	11.3
Tata Motors   Neutral   712   690   73   632   508   520   7.7   7.9   6.3   8.1   8.1   8.1   8.1   8.1   1.0   8.2   8.1   1.0   8.2   8.1   1.0   8.2	Motherson Wiring	Buy	61	68	11	1.4	1.6	2.0	-5.1	19.9	22.4	44.7	37.2	15.9	13.2	35.9	38.8
TVS Motor   Neutral   2742   2720	Sona BLW Precis.	Neutral	502	490	-2	9.9	9.8	11.0	10.5	-1.1	12.3	50.8	51.4	5.5	5.2	14.5	10.5
Part	Tata Motors	Neutral	712	690	-3	63.2	50.8	52.0	7.7	-19.6	2.2	11.3	14.0	2.3	2.0	23.1	15.0
Magregate	TVS Motor	Neutral	2742	2720	-1	57.1	66.3	78.4	30.1	16.3	18.1	48.1	41.3	13.1	10.4	30.7	28.1
Banks - Private   Buy   768   775   1   29.8   36.9   49.7   29.7   24   34.6   25.8   20.8   3.4   3.0   14.3   15.2   14.6   15.0   15.0	Tube Investments	Buy	2939	3658	24	38.6	41.8	47.1	1.6	8.2	12.8	76.1	70.4	10.9	9.6	16.3	14.5
AU Small Finance Buy 768 775 1 29.8 36.9 49.7 29.7 24 34.6 25.8 20.8 3.4 3.0 14.3 15.2 Axis Bank Neutral 1206 1300 8 85.4 90.9 107.1 5.9 6.4 17.8 14.1 13.3 2.1 1.8 15.9 14.6 Bandhan Bank Neutral 175 170 -3 17.0 19.8 23.9 23.1 16 20.8 10.3 8.8 1.1 1.1 11.9 12.7 DCB Bank Buy 145 165 14 19.6 24.2 31.0 14.3 23.6 28.3 7.4 6.0 0.8 0.7 12.1 13.3 Equitas Small Fin. Buy 68 77 13 1.3 4.0 8.9 81.8 209.1 123.1 52.8 17.1 1.3 1.2 2.4 7.4 Federal Bank Buy 205 230 12 16.6 18.0 22.5 1.8 8.4 24.9 12.3 11.4 1.5 1.4 13.0 12.5 HDFC Bank Buy 1917 2200 15 88.7 96.7 112.6 10.7 9.1 16.4 21.6 19.8 2.9 2.6 14.3 14.0 15.1 HDFC Bank Buy 1416 1650 17 66.8 72.9 85.5 14.4 9.2 17.3 21.2 19.4 3.5 3.1 18.0 17.1 IDFC First Bk Neutral 70 72 2 2.1 3.5 5.8 50.9 64.7 66.1 33.2 20.2 1.4 1.3 4.4 6.5 Industand Neutral 817 650 -20 33.1 14.2 57.0 -71.4 33.8 28.8 24.7 19.2 19.4 3.5 3.1 18.0 17.1 IDFC Bink Buy 205 20 0 11.5 22.6 35.6 40.5 96.4 57.8 19.2 98.0 0.9 0.8 4.6 8.6 Ragegaete	Aggregate								6.9	3.8	13.0	26.1	25.2	4.6	4.1	17.7	16.3
Axis Bank         Neutral         1206         1300         8         85.4         90.9         107.1         5.9         6.4         17.8         14.1         13.3         2.1         1.8         15.9         14.6           Bandhan Bank         Neutral         175         170         -3         17.0         19.8         23.9         23.1         16         20.8         10.3         8.8         1.1         1.1         11.9         12.7           DCB Bank         Buy         145         165         14         19.6         24.2         31.0         14.3         23.6         28.3         7.4         6.0         0.8         0.7         12.1         13.3           Equitas Small Fin.         Buy         1917         200         15         88.7         96.7         112.6         10.7         91.         16.4         19.8         19.9         2.6         14.3         14.0           HDFC Bank         Buy         1917         2200         15         88.7         96.7         112.6         10.7         91.         16.4         19.8         19.8         2.9         2.6         14.3         14.0           IDFC Bank         Buy         1416         16	Banks - Private																
Bandhan Bank   Neutral   175   170   -3   17.0   19.8   23.9   23.1   16   20.8   10.3   8.8   1.1   1.1   11.9   12.7	AU Small Finance	Buy	768	775	1	29.8	36.9	49.7	29.7	24	34.6	25.8	20.8	3.4	3.0	14.3	15.2
DCB Bank         Buy         145         165         14         19.6         24.2         31.0         14.3         23.6         28.3         7.4         6.0         0.8         0.7         12.1         13.3         4.0         8.9         -81.8         209.1         123.1         52.8         17.1         1.3         1.2         2.4         7.4           Federal Bank         Buy         205         230         12         16.6         18.0         22.5         1.8         8.4         24.9         12.3         11.4         1.5         1.4         13.0         12.5           HDFC Bank         Buy         1917         2200         15         88.7         96.7         112.6         10.7         9.1         16.4         21.6         19.8         2.9         2.6         14.3         14.0           ICICI Bank         Buy         1416         1650         17         66.8         72.9         85.5         14.4         9.2         17.3         21.2         19.4         3.5         3.1         18.0         17.1           IDFC First Bk         Neutral         817         650         -20         33.1         44.2         57.0         -71.4         33.2	Axis Bank	Neutral	1206	1300	8	85.4	90.9	107.1	5.9	6.4	17.8	14.1	13.3	2.1	1.8	15.9	14.6
Equitas Small Fin.         Buy         68         77         13         1.3         4.0         8.9         81.8         209.1         123.1         52.8         17.1         1.3         1.2         2.4         7.4           Federal Bank         Buy         205         230         12         16.6         18.0         22.5         1.8         8.4         24.9         12.3         11.4         1.5         1.4         13.0         12.5           HDFC Bank         Buy         1917         2200         15         88.7         96.7         112.6         10.7         9.1         16.4         21.6         19.8         2.9         2.6         14.3         14.0           ICICI Bank         Buy         1416         1650         17         66.8         72.9         85.5         14.4         9.2         17.3         21.2         14.4         1.0         11.0 </td <td>Bandhan Bank</td> <td>Neutral</td> <td>175</td> <td>170</td> <td>-3</td> <td>17.0</td> <td>19.8</td> <td>23.9</td> <td>23.1</td> <td>16</td> <td>20.8</td> <td>10.3</td> <td>8.8</td> <td>1.1</td> <td>1.1</td> <td>11.9</td> <td>12.7</td>	Bandhan Bank	Neutral	175	170	-3	17.0	19.8	23.9	23.1	16	20.8	10.3	8.8	1.1	1.1	11.9	12.7
Federal Bank         Buy         205         230         12         16.6         18.0         22.5         1.8         8.4         24.9         12.3         11.4         1.5         1.4         13.0         12.5           HDFC Bank         Buy         1917         2200         15         88.7         96.7         112.6         10.7         9.1         16.4         21.6         19.8         2.9         2.6         14.3         14.0           ICICI Bank         Buy         1416         1650         17         66.8         72.9         85.5         14.4         9.2         17.3         21.2         19.4         3.5         3.1         18.0         17.1           IDFC First Bk         Neutral         70         72         2         2.1         3.5         5.8         -50.9         64.7         66.1         33.2         20.2         1.4         1.3         44.4         6.5           IndusInd         Neutral         817         650         -20         33.1         44.2         57.0         -71.4         33.8         28.8         24.7         18.5         1.0         0.9         4.0         5.2           Kotak Mah. Bk         Buy         211 <td>DCB Bank</td> <td>Buy</td> <td>145</td> <td>165</td> <td>14</td> <td>19.6</td> <td>24.2</td> <td>31.0</td> <td>14.3</td> <td>23.6</td> <td>28.3</td> <td>7.4</td> <td>6.0</td> <td>8.0</td> <td>0.7</td> <td>12.1</td> <td>13.3</td>	DCB Bank	Buy	145	165	14	19.6	24.2	31.0	14.3	23.6	28.3	7.4	6.0	8.0	0.7	12.1	13.3
HDFC Bank Buy 1917 2200 15 88.7 96.7 112.6 10.7 9.1 16.4 21.6 19.8 2.9 2.6 14.3 14.0 ICICI Bank Buy 1416 1650 17 66.8 72.9 85.5 14.4 9.2 17.3 21.2 19.4 3.5 3.1 18.0 17.1 IDFC First Bk Neutral 70 72 2 2 2.1 3.5 5.8 -50.9 64.7 66.1 33.2 20.2 1.4 1.3 4.4 6.5 IndusInd Neutral 817 650 -20 33.1 44.2 57.0 -71.4 33.8 28.8 24.7 18.5 1.0 0.9 4.0 5.2 Kotak Mah. Bk Buy 2111 2500 18 110.4 108.9 129.1 20.5 -1.3 18.6 19.1 19.4 2.8 2.4 12.8 12.6 RBL Bank Buy 220 220 0 11.5 22.6 35.6 -40.5 96.4 57.8 19.2 9.8 0.9 0.8 4.6 8.6 Aggregate  BOB Neutral 239 250 5 37.8 39.4 43.6 10.1 4.3 10.5 6.3 6.1 0.9 0.9 16.4 15.1 Canara Bank Buy 111 115 3 18.8 19.7 21.8 17.0 4.9 10.6 5.9 5.7 1.1 0.9 20.2 18.3 Indian Bank Buy 625 670 7 81.1 84.4 94.3 30.3 4.1 11.7 7.7 7.4 1.3 1.2 18.9 17.0 Punjab Natl.Bank Buy 792 925 17 86.9 90.1 10.8 15.6 4 15.2 9.1 8.8 1.5 1.3 18.6 16.1 Union Bank (I) Buy 792 925 17 86.9 90.1 10.8 15.6 4 15.2 9.1 8.8 1.5 1.3 18.6 16.1 Union Bank (I) Buy 146 145 -1 23.6 24.2 25.9 24.9 3 6.7 6.2 6.0 1.0 0.9 18.1 16.2 15.3 NBFCS  AAVAS Financiers Neutral 1849 2070 12 72.5 86.6 102.7 17.0 19.4 18.6 25.5 21.4 3.4 2.9 14.1 14.6 4.1 14.6 4.1 14.6 14.5 14.9 18.5 14.5 16.6 24.3 18.8 16.1 2.1 1.9 11.6 12.1 1.0 14.6 14.5 14.9 18.6 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5	Equitas Small Fin.	Buy	68	77	13	1.3	4.0	8.9	-81.8	209.1	123.1	52.8	17.1	1.3	1.2	2.4	7.4
ICICI Bank   Buy   1416   1650   17   66.8   72.9   85.5   14.4   9.2   17.3   21.2   19.4   3.5   3.1   18.0   17.1     IDFC First Bk   Neutral   70   72   2   2.1   3.5   5.8   -5.9   64.7   66.1   33.2   20.2   1.4   1.3   4.4   6.5     IndusInd   Neutral   817   650   -20   33.1   44.2   57.0   -71.4   33.8   28.8   24.7   18.5   1.0   0.9   4.0   5.2     Kotak Mah. Bk   Buy   2111   2500   18   110.4   108.9   129.1   20.5   -1.3   18.6   19.1   19.4   2.8   2.4   12.8   12.6     RBL Bank   Buy   220   220   0   11.5   22.6   35.6   -40.5   96.4   57.8   19.2   9.8   0.9   0.8   4.6   8.6     Aggregate	Federal Bank	Buy	205	230	12	16.6	18.0	22.5	1.8	8.4	24.9	12.3	11.4	1.5	1.4	13.0	12.5
IDFC First Bk	HDFC Bank	Buy	1917	2200	15	88.7	96.7	112.6	10.7	9.1	16.4	21.6	19.8	2.9	2.6	14.3	14.0
Industed   Neutral   817   650   -20   33.1   44.2   57.0   -71.4   33.8   28.8   24.7   18.5   1.0   0.9   4.0   5.2	ICICI Bank	Buy	1416	1650	17	66.8	72.9	85.5	14.4	9.2	17.3	21.2	19.4	3.5	3.1	18.0	17.1
Kotak Mah. Bk         Buy         2111         2500         18         110.4         108.9         129.1         20.5         -1.3         18.6         19.1         19.4         2.8         2.4         12.8         12.6           RBL Bank         Buy         220         220         0         11.5         22.6         35.6         -40.5         96.4         57.8         19.2         9.8         0.9         0.8         4.6         8.6           Aggregate         6.4         9.5         19.3         20.1         18.4         2.8         2.5         13.7         13.6           Banks - PSU           BOB         Neutral         239         250         5         37.8         39.4         43.6         10.1         4.3         10.5         6.3         6.1         0.9         0.9         16.4         15.1           Canara Bank         Buy         111         115         3         18.8         19.7         21.8         17.0         4.9         10.6         5.9         5.7         1.1         0.9         20.2         18.3           Indian Bank         Buy         625         670         7         81.1         84.4	IDFC First Bk	Neutral	70	72	2	2.1	3.5	5.8	-50.9	64.7	66.1	33.2	20.2	1.4	1.3	4.4	6.5
RBL Bank         Buy         220         220         0         11.5         22.6         35.6         -40.5         96.4         57.8         19.2         9.8         0.9         0.8         4.6         8.6           Aggregate         6.4         9.5         19.3         20.1         18.4         2.8         2.5         13.7         13.6           Banks - PSU           BOB         Neutral         239         250         5         37.8         39.4         43.6         10.1         4.3         10.5         6.3         6.1         0.9         0.9         16.4         15.1           Canara Bank         Buy         111         115         3         18.8         19.7         21.8         17.0         4.9         10.6         5.9         5.7         1.1         0.9         20.2         18.3           Indian Bank         Buy         625         670         7         81.1         84.4         94.3         30.3         4.1         11.7         7.7         7.4         1.3         1.2         18.9         17.0           Punjab Natl.Bank         Buy         107         125         17         86.9         90.1 <t< td=""><td>IndusInd</td><td>Neutral</td><td>817</td><td>650</td><td>-20</td><td>33.1</td><td>44.2</td><td>57.0</td><td>-71.4</td><td>33.8</td><td>28.8</td><td>24.7</td><td>18.5</td><td>1.0</td><td>0.9</td><td>4.0</td><td>5.2</td></t<>	IndusInd	Neutral	817	650	-20	33.1	44.2	57.0	-71.4	33.8	28.8	24.7	18.5	1.0	0.9	4.0	5.2
Aggregate       6.4       9.5       19.3       20.1       18.4       2.8       2.5       13.7       13.6         Banks - PSU         BOB       Neutral       239       250       5       37.8       39.4       43.6       10.1       4.3       10.5       6.3       6.1       0.9       0.9       16.4       15.1         Canara Bank       Buy       111       115       3       18.8       19.7       21.8       17.0       4.9       10.6       5.9       5.7       1.1       0.9       20.2       18.3         Indian Bank       Buy       625       670       7       81.1       84.4       94.3       30.3       4.1       11.7       7.7       7.4       1.3       1.2       18.9       17.0         Punjab Natl.Bank       Buy       107       125       17       14.8       16.9       19.4       97.4       14.5       14.9       7.2       6.3       1.0       0.9       15.3       15.3         SBI       Buy       792       925       17       86.9       90.1       103.8       15.6       4       15.2       9.1       8.8       1.5       1.3       18.6	Kotak Mah. Bk	Buy	2111	2500	18	110.4	108.9	129.1	20.5	-1.3	18.6	19.1	19.4	2.8	2.4	12.8	12.6
Banks - PSU           BOB         Neutral         239         250         5         37.8         39.4         43.6         10.1         4.3         10.5         6.3         6.1         0.9         0.9         16.4         15.1           Canara Bank         Buy         111         115         3         18.8         19.7         21.8         17.0         4.9         10.6         5.9         5.7         1.1         0.9         20.2         18.3           Indian Bank         Buy         625         670         7         81.1         84.4         94.3         30.3         4.1         11.7         7.7         7.4         1.3         1.2         18.9         17.0           Punjab Natl.Bank         Buy         107         125         17         14.8         16.9         19.4         97.4         14.5         14.9         7.2         6.3         1.0         0.9         15.3         15.3           SBI         Buy         792         925         17         86.9         90.1         103.8         15.6         4         15.2         9.1         8.8         1.5         1.3         18.6         16.1           Union Bank (I)	RBL Bank	Buy	220	220	0	11.5	22.6	35.6	-40.5	96.4	57.8	19.2	9.8	0.9	0.8	4.6	8.6
BOB         Neutral         239         250         5         37.8         39.4         43.6         10.1         4.3         10.5         6.3         6.1         0.9         0.9         16.4         15.1           Canara Bank         Buy         111         115         3         18.8         19.7         21.8         17.0         4.9         10.6         5.9         5.7         1.1         0.9         20.2         18.3           Indian Bank         Buy         625         670         7         81.1         84.4         94.3         30.3         4.1         11.7         7.7         7.4         1.3         1.2         18.9         17.0           Punjab Natl.Bank         Buy         107         125         17         14.8         16.9         19.4         97.4         14.5         14.9         7.2         6.3         1.0         0.9         15.3         15.3           SBI         Buy         792         925         17         86.9         90.1         103.8         15.6         4         15.2         9.1         8.8         1.5         1.3         18.6         16.1           Union Bank (I)         Buy         146         145	Aggregate								6.4	9.5	19.3	20.1	18.4	2.8	2.5	13.7	13.6
Canara Bank         Buy         111         115         3         18.8         19.7         21.8         17.0         4.9         10.6         5.9         5.7         1.1         0.9         20.2         18.3           Indian Bank         Buy         625         670         7         81.1         84.4         94.3         30.3         4.1         11.7         7.7         7.4         1.3         1.2         18.9         17.0           Punjab Natl.Bank         Buy         107         125         17         14.8         16.9         19.4         97.4         14.5         14.9         7.2         6.3         1.0         0.9         15.3         15.3           SBI         Buy         792         925         17         86.9         90.1         103.8         15.6         4         15.2         9.1         8.8         1.5         1.3         18.6         16.1           Union Bank (I)         Buy         146         145         -1         23.6         24.2         25.9         24.9         3         6.7         6.2         6.0         1.0         0.9         18.1         16.2           Aggregate         23.4         5 <td>Banks - PSU</td> <td></td>	Banks - PSU																
Indian Bank         Buy         625         670         7         81.1         84.4         94.3         30.3         4.1         11.7         7.7         7.4         1.3         1.2         18.9         17.0           Punjab Natl.Bank         Buy         107         125         17         14.8         16.9         19.4         97.4         14.5         14.9         7.2         6.3         1.0         0.9         15.3         15.3           SBI         Buy         792         925         17         86.9         90.1         103.8         15.6         4         15.2         9.1         8.8         1.5         1.3         18.6         16.1           Union Bank (I)         Buy         146         145         -1         23.6         24.2         25.9         24.9         3         6.7         6.2         6.0         1.0         0.9         18.1         16.2           Aggregate         23.4         5         13         8         7.6         1.3         1.2         16.2         15.3           NBFCs           AAVAS Financiers         Neutral         1849         2070         12         72.5 <td< td=""><td>ВОВ</td><td>Neutral</td><td>239</td><td>250</td><td>5</td><td>37.8</td><td>39.4</td><td>43.6</td><td>10.1</td><td>4.3</td><td>10.5</td><td>6.3</td><td>6.1</td><td>0.9</td><td>0.9</td><td>16.4</td><td>15.1</td></td<>	ВОВ	Neutral	239	250	5	37.8	39.4	43.6	10.1	4.3	10.5	6.3	6.1	0.9	0.9	16.4	15.1
Punjab Natl.Bank       Buy       107       125       17       14.8       16.9       19.4       97.4       14.5       14.9       7.2       6.3       1.0       0.9       15.3       15.3         SBI       Buy       792       925       17       86.9       90.1       103.8       15.6       4       15.2       9.1       8.8       1.5       1.3       18.6       16.1         Union Bank (I)       Buy       146       145       -1       23.6       24.2       25.9       24.9       3       6.7       6.2       6.0       1.0       0.9       18.1       16.2         Aggregate       23.4       5       13       8       7.6       1.3       1.2       16.2       15.3         NBFCs         AAVAS Financiers       Neutral       1849       2070       12       72.5       86.6       102.7       17.0       19.4       18.6       25.5       21.4       3.4       2.9       14.1       14.6         Aditya Birla Cap       Buy       240       250       4       12.8       14.9       18.5       14.5       16.6       24.3       18.8       16.1       2.1       1.9 </td <td>Canara Bank</td> <td>Buy</td> <td>111</td> <td>115</td> <td>3</td> <td>18.8</td> <td>19.7</td> <td>21.8</td> <td>17.0</td> <td>4.9</td> <td>10.6</td> <td>5.9</td> <td>5.7</td> <td>1.1</td> <td>0.9</td> <td>20.2</td> <td>18.3</td>	Canara Bank	Buy	111	115	3	18.8	19.7	21.8	17.0	4.9	10.6	5.9	5.7	1.1	0.9	20.2	18.3
SBI     Buy     792     925     17     86.9     90.1     103.8     15.6     4     15.2     9.1     8.8     1.5     1.3     18.6     16.1       Union Bank (I)     Buy     146     145     -1     23.6     24.2     25.9     24.9     3     6.7     6.2     6.0     1.0     0.9     18.1     16.2       Aggregate     23.4     5     13     8     7.6     1.3     12.2     16.2     15.3       NBFCs       AAVAS Financiers     Neutral     1849     2070     12     72.5     86.6     102.7     17.0     19.4     18.6     25.5     21.4     3.4     2.9     14.1     14.6       Aditya Birla Cap     Buy     240     250     4     12.8     14.9     18.5     14.5     16.6     24.3     18.8     16.1     2.1     1.9     11.6     12.1	Indian Bank	Buy	625	670	7	81.1	84.4	94.3	30.3	4.1	11.7	7.7	7.4	1.3	1.2	18.9	17.0
Union Bank (I) Buy 146 145 -1 23.6 24.2 25.9 24.9 3 6.7 6.2 6.0 1.0 0.9 18.1 16.2 Aggregate 23.4 5 13 8 7.6 1.3 1.2 16.2 15.3 NBFCs  AAVAS Financiers Neutral 1849 2070 12 72.5 86.6 102.7 17.0 19.4 18.6 25.5 21.4 3.4 2.9 14.1 14.6 Aditya Birla Cap Buy 240 250 4 12.8 14.9 18.5 14.5 16.6 24.3 18.8 16.1 2.1 1.9 11.6 12.1	Punjab Natl.Bank	Buy	107	125	17	14.8	16.9	19.4	97.4	14.5	14.9	7.2	6.3	1.0	0.9	15.3	15.3
Union Bank (I) Buy 146 145 -1 23.6 24.2 25.9 24.9 3 6.7 6.2 6.0 1.0 0.9 18.1 16.2 Aggregate 23.4 5 13 8 7.6 1.3 1.2 16.2 15.3 NBFCs  AAVAS Financiers Neutral 1849 2070 12 72.5 86.6 102.7 17.0 19.4 18.6 25.5 21.4 3.4 2.9 14.1 14.6 Aditya Birla Cap Buy 240 250 4 12.8 14.9 18.5 14.5 16.6 24.3 18.8 16.1 2.1 1.9 11.6 12.1	SBI	Buy	792	925	17	86.9	90.1	103.8	15.6	4	15.2	9.1	8.8	1.5	1.3	18.6	16.1
NBFCs       AAVAS Financiers     Neutral     1849     2070     12     72.5     86.6     102.7     17.0     19.4     18.6     25.5     21.4     3.4     2.9     14.1     14.6       Aditya Birla Cap     Buy     240     250     4     12.8     14.9     18.5     14.5     16.6     24.3     18.8     16.1     2.1     1.9     11.6     12.1	Union Bank (I)	Buy	146	145	-1	23.6	24.2	25.9	24.9	3	6.7	6.2	6.0	1.0	0.9	18.1	16.2
AAVAS Financiers Neutral 1849 2070 12 72.5 86.6 102.7 17.0 19.4 18.6 25.5 21.4 3.4 2.9 14.1 14.6 Aditya Birla Cap Buy 240 250 4 12.8 14.9 18.5 14.5 16.6 24.3 18.8 16.1 2.1 1.9 11.6 12.1	Aggregate								23.4	5	13	8	7.6	1.3	1.2	16.2	15.3
Aditya Birla Cap Buy 240 250 4 12.8 14.9 18.5 14.5 16.6 24.3 18.8 16.1 2.1 1.9 11.6 12.1	NBFCs																
	AAVAS Financiers	Neutral	1849	2070	12	72.5	86.6	102.7	17.0	19.4	18.6	25.5	21.4	3.4	2.9	14.1	14.6
	Aditya Birla Cap	Buy	240	250	4	12.8	14.9	18.5	14.5	16.6	24.3	18.8	16.1	2.1	1.9	11.6	12.1
	Bajaj Fin.	Neutral	9334	10000	7		338.8	424.8	15.5	25.5	25.4	34.6	27.6	6.0	5.1	19.3	19.9







## Valuation snapshot

		СМР	TP	% Upside		EPS (INR	)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Can Fin Homes	Neutral	793	770	-3	64.4	70.4	79.9	14.2	9.3	13.5	12.3	11.3	2.1	1.8	18.2	17.2
Cholaman.Inv.&Fn	Buy	1556	1770	14	50.6	65.2	83.6	24.3	28.8	28.3	30.7	23.9	5.5	4.3	19.7	20.5
CreditAccess	Buy	1180	1425	21	33.3	54.7	103.3	-63.3	64.5	88.8	35.5	21.6	2.7	2.4	7.9	11.8
Fusion Finance	Neutral	194	170	-12	-121.7	13.2	25.5	-342.3	LP	93.1	NM	14.6	1.2	1.4	-54.5	9.0
Five-Star Business	Buy	768	840	9	36.4	40.4	47.0	27.4	11.0	16.2	21.1	19.0	3.6	3.0	18.7	17.3
IIFL Finance	Buy	469	520	11	8.9	37.8	49.5	-80.7	323.4	31.1	52.5	12.4	1.6	1.4	3.3	12.2
Home First Finan	Buy	1269	1500	18	42.4	51.4	62.8	22.8	21.2	22.2	29.9	24.7	4.5	3.1	16.5	15.6
IndoStar	Buy	333	360	8	3.9	8.0	13.5	-26.6	107.3	68.3	86.2	41.6	1.3	1.0	1.6	2.9
L&T Finance	Buy	186	200	8	10.6	12.4	16.0	13.8	16.9	29.6	17.5	15.0	1.8	1.7	10.8	11.5
LIC Hsg Fin	Neutral	600	670	12	98.6	95.7	102.9	13.9	-2.9	7.4	6.1	6.3	0.9	0.8	16.0	13.7
Manappuram Fin.	Neutral	280	240	-14	14.2	21.5	26.0	-45.2	51.0	20.9	19.7	13.0	1.9	1.6	10.0	13.8
MAS Financial	Buy	291	320	10	16.9	21.0	25.9	11.6	24.8	23.0	17.2	13.8	2.1	1.8	14.4	14.1
M&M Fin.	Buy	271	335	24	19.0	23.3	29.3	33.2	22.8	25.8	14.3	11.6	1.7	1.5	12.4	13.8
Muthoot Fin	Neutral	2600	2500	-4	129.5	171.3	193.0	28.4	32.3	12.6	20.1	15.2	3.7	3.1	19.7	22.1
Piramal Enterp.	Neutral	1133	1085	-4	21.5	58.8	68.2	-306.2	173.2	16.1	52.7	19.3	0.9	0.9	1.8	4.8
PNB Housing	Buy	1056	1230	17	74.5	87.8	102.9	28.3	17.9	17.2	14.2	12.0	1.6	1.4	12.2	12.7
Poonawalla	Duny	417	440	6	-1.3	12.6	22.7	-109.5	LP	80.4	NM	33.1	4.0	3.5	-1.2	11.3
Fincorp	Buy	417	440	0	-1.5	12.0	22.7	-109.5	LP	60.4	INIVI	33.1	4.0	3.3	-1.2	11.5
PFC	Buy	406	485	19	52.6	54.7	60.9	20.8	4.1	11.4	7.7	7.4	1.5	1.3	20.4	18.6
REC	Buy	403	460	14	59.7	66.4	73.6	12.2	11.1	11.0	6.7	6.1	1.4	1.2	21.5	20.8
Repco Home Fin	Neutral	427	465	9	70.2	69.6	74.9	11.3	-0.9	7.7	6.1	6.1	0.8	0.7	14.2	12.4
Spandana Sphoorty	Buy	276	340	23	-145.2	-21.0	28.5	-306.7	Loss	LP	NM	NM	0.7	0.8	-33.0	-5.9
Shriram Finance	Buy	668	800	20	44.0	52.9	62.7	14.9	20.3	18.5	15.2	12.6	2.2	1.9	15.8	16.4
Aggregate	,							6.9	23.4	19.9	18.4	14.9	2.6	2.3	14.4	15.3
NBFC-Non Lending	,															
360 ONE WAM	Buy	1140	1300	14	25.8	32.8	37.3	15.3	26.9	13.9	44.2	34.8	6.3	5.9	19.3	17.6
Aditya Birla AMC	Buy	767	780	2	32.3	35.2	40.1	19.3	9.0	13.8	23.7	21.8	5.9	5.3	27.0	25.7
Anand Rathi	· ·															
Wealth	Neutral	2014	1900	-6	36.2	44.3	51.8	33.7	22.4	17.1	55.7	45.5	24.9	17.5	45.5	45.0
Angel One	Buy	2926	2800	-4	129.8	106.6	150.6	-3.1	-17.9	41.2	22.5	27.4	4.3	3.9	27.1	16.2
BSE	Buy	2711	2533	-7	32.4	48.2	57.1	67.2	48.6	18.5	83.6	56.2	24.9	18.6	29.8	33.0
Cams Services	Buy	3981	4300	8	94.8	103.5	120.2	32.4	9.2	16.1	42.0	38.4	17.4	14.8	45.7	41.6
CDSL	Neutral	1660	1150	-31	25.1	25.7	32.1	24.8	2.5	24.9	66.2	64.6	19.7	17.0	32.5	28.3
HDFC AMC	Buy	4968	5000	1	115.2	131.3	149.0	26.6	14.0	13.4	43.1	37.8	13.0	12.0	32.4	33.1
KFin Technologies	Neutral	1208	1150	-5	19.5	22.6	28.5	33.9	15.8	26.2	62.0	53.6	15.8	14.2	28.3	27.9
MCX	Neutral	7558	6000	-21	110.1	142.2	178.0	573.8	29.1	25.2	68.7	53.2	20.4	18.9	34.3	37.0
Nippon Life AMC	Buy	736	750	2	20.4	22.6	25.5	16.2	10.6	12.9	36.0	32.6	11.0	10.8	31.4	33.5
Nuvama Wealth	Buy	7092	8600	21	276.9	331.6	392.7	64.5	19.7	18.4	25.6	21.4	7.2	6.2	30.8	31.2
Prudent Corp.	Neutral	2837	2300	-19	47.3	54.1	69.0	41.1	14.4	27.7	60.0	52.5	88.0	67.8	34.1	29.2
UTI AMC	Buy	1225	1550	27	63.9	71.3	82.4	1.4	11.6	15.6	19.2	17.2	3.0	2.9	16.0	17.0
Aggregate								31.3	15.5	18.3	43.8	37.9	11.0	9.8	25.1	25.9
Insurance																
HDFC Life Insur.	Buy	752	850	13	8.4	10.2	11.5	14.9	21.2	13.3	89.8	74.1	2.9	2.5	16.7	16.9
ICICI Lombard	Buy	1941	2200	13	50.9	57.9	67.0	30.7	13.7	15.8	38.1	33.5	6.7	5.8	19.1	18.6
ICICI Pru Life	Buy	629	680	8	8.2	10.3	12.3	39.0	25.5	19.4	76.5	61.0	1.9	1.7	13.3	13.0
Life Insurance Corp.	Buy	938	1050	12	76.1	82.1	93.0	18.8	7.8	13.3	12.3	11.4	8.0	0.7	6.8	11.7
Max Financial	Neutral	1528	1330	-13	9.3	16.4	21.5	23.6	75.9	30.9	163.5	92.9	2.6	2.2	29.2	19.4
Niva Bupa Health	Buy	81	100	23	1.2	0.8	1.6	142.7	-33.9	112.4	69.6	105.4	4.9	3.8	7.9	4.0
SBI Life Insurance	Buy	1754	2000	14	24.1	28.5	33.8	27.4	18.0	18.9	72.7	61.6	2.5	2.1	20.6	19.3
Star Health Insu	Buy	444	460	4	11.0	13.6	18.4	-23.9	24.1	35.1	40.4	32.5	3.7	3.3	9.5	10.8
Chemicals																
Alkyl Amines	Neutral	1990	1640	-18	36.3	41.1	46.9	24.8	13.0	14.1	54.7	48.4	7.3	6.6	13.9	14.2
Atul	Buy	7014	8450	20	169.3	222.1	241.4	53.9	31.2	8.7	41.4	31.6	3.7	3.4	9.3	11.1
Clean Science	Neutral	1466	1260	-14	24.9	34.0	42.0	8.3	36.6	23.5	58.9	43.1	11.0	9.1	20.2	23.0





## Valuation snapshot

		Chro		0/ 1111		EDC (INIE)	1	EDC	C- V '	/o/\	p./-	. ()	5./-	2.63		10/1
	_	CMP	TP	% Upside		EPS (INR			Gr. YoY	• •	P/E (x) P					(%)
Company	Reco	(INR)	(INR)	Downside		FY26E	FY27E	FY24								
Deepak Nitrite	Sell	1912	1650	-14	51.1	61.5	66.1	-7.3	20.3	7.5	37.4	31.1	4.8	4.3	13.7	14.6
Fine Organic	Sell	4746	3660	-23	127.1	122.7	122.0	5.9	-3.5	-0.5	37.3	38.7	6.6	5.7	19.1	15.7
Galaxy Surfact.	Buy	2373	3180	34	86.0	93.2	106.0	1.1	8.4	13.8	27.6	25.5	3.6	3.2	13.4	13.3
Navin Fluorine	Neutral	4546	5060	11	58.2	89.4	112.4	26.2	53.6	25.8	78.1	50.9	8.6	7.6	11.5	15.8
NOCIL	Neutral	199	170	-15	6.4	6.4	8.5	-18.3	-0.8	32.7	30.9	31.1	1.9	1.8	6.3	6.0
PI Inds.	Buy	3975	4300	8	109.2	108.5	129.7	-1.3	-0.6	19.5	36.4	36.6	5.9	5.2	17.6	15.2
SRF	Buy	3098	3500	13	46.1	70.9	98.7	-3.0	54.0	39.1	67.3	43.7	7.3	6.5	11.4	15.7
Tata Chemicals	Neutral	925	870	-6	11.6	35.1	54.6	-67.9	202.4	55.7	79.7	26.4	1.1	1.0	1.3	4.0
Vinati Organics	Buy	1880	2195	17	40.0	51.3	62.7	28.4	28.2	22.1	46.9	36.6	6.9	6.0	15.8	17.6
Aggregate								9.6	21.3	12.8	44.6	36.7	5.4	4.8	12.0	13.0
Capital Goods	D	F007	C400		00.5	04.4	102.6	F0.2	C 7	0.7	67.0	C2 F	10.0	15.7	20.0	26.4
ABB India	Buy	5997	6400	7	88.5	94.4	103.6	50.2	6.7	9.7	67.8	63.5	18.0	15.7	28.8	26.4
Bharat Electronics	Buy	394	410	4	7.2	8.4	10.2	31.5	15.5	21.9	54.5	47.2	14.6	11.5	26.8	24.3
Cummins India	Buy	3313	4060	23	71.7	84.6	99.1	16.6	18.0	17.1	46.2	39.2	13.1	11.6	30.2	31.4
Hind.Aeronautics	Buy	5027	5650	12	125.0	141.2	161.2	38.4	13.0	14.2	40.2	35.6	9.6	8.1	23.9	22.6
Hitachi Energy	Sell	17783	12500	-30	77.5	170.1	250.0	100.5	119.6	47.0		104.6	17.9	15.2	8.2	15.3
Kalpataru Proj.	Buy	1161	1300	12	39.3	55.4	74.1	20.3	40.8	33.9	29.5	21.0	2.8	2.5	10.4	12.4
KEC International	Neutral	876	940	7	21.4	35.1	44.4	64.6	63.5	26.8	40.8	25.0	4.4	4.2	12.1	17.2
Kirloskar Oil	Buy	882	1150	30	28.8	33.6	40.9	15.1	16.7	21.8	30.7	26.3	4.3	3.8	14.9	15.3
Larsen & Toubro	Buy	3588	3950	10	105.9	127.3	156.7	12.3	20.2	23.0	33.9	28.2	5.1	4.5	15.8	16.9
Siemens	Neutral	3261	3200	-2	76.3	76.5	92.4	38.5	0.2	20.8	42.7	42.6	7.6	6.7	19.1	16.6
Thermax	Sell	3550	3100	-13	56.4	65.7	77.9	8.1	16.5	18.6	63.0	54.0	8.1	7.3	13.5	14.2
Triveni Turbine	Buy	601	700	16	11.3	12.8	16.0	33.2	13.8	25.0	53.3	46.8	15.7	12.7	33.0	29.9
Zen Technologies	Neutral	1975	1750	-11	29.1	37.9	57.1	107.3	30.3	50.5	67.8	52.1	10.6	8.8	24.6	18.4
Aggregate								25.4	17.6	20.8	43.4	36.9	7.9	6.9	18.2	18.6
Cement	Divis	F 42	620	4.4	0.0	40.6	45.0	42.6	22.2	40.0	60.4	F4.4	2.5	2.4	4.4	4.0
Ambuja Cem.	Buy	543	620	14	8.0	10.6	15.0	-42.6	33.3	40.9	68.1	51.1	2.5	2.4	4.1	4.8
ACC	Buy	1847	2400	30	71.2	89.1	120.9	-28.3	25.2	35.6	25.9	20.7	1.9	1.8	7.8	8.8
Birla Corp.	Buy	1354	1540	14	42.2	62.4	76.5	-21.8	47.7	22.7	32.1	21.7	1.5	1.4	4.8	6.7
Dalmia Bhar.	Buy	2089	2300	10	37.1	59.5	69.2	-9.0	60.6	16.2	56.3	35.1	2.3	2.1	4.1	6.3
Grasim Inds.	Buy	2665	3170	19	74.1	89.9	110.7	-22.5	21.3	23.2	36.0	29.7	3.3	3.2	-4.3	-2.7
India Cem	Sell	333	240	-28	-24.0	-3.9	3.0	216.9	Loss	LP	NM	NM 47.0	1.1	1.1	-9.9	-1.3
J K Cements	Buy	6096	6060	-1	103.5	129.6	172.3	0.8	25.2	32.9	58.9	47.0	7.7	6.8	13.5	15.4
JK Lakshmi Ce	Buy	834	1000	20	26.3	40.6	45.7	-33.2	54.6	12.5	31.7	20.5	2.8	2.5	9.3	13.0
Ramco Cem	Neutral	1063	1030	-3	3.9	20.9	29.6	-76.6	433.4	41.5	271.4	50.9	3.4	3.2	1.3	6.4
Shree Cem	Neutral	29644	29300		337.9	350.8	482.0	-50.6	3.8	37.4	87.7	84.5	5.0	4.9	5.9	5.9
Ultratech	Buy	11221	13900	24	207.6	295.8	372.1	-15.1	42.5	25.8	54.1	37.9	4.7	4.3	9.3	11.8
Aggregate								-27.2	39.1	29.0	54.0	38.8	3.4	3.2	6.4	8.3
Consumer	Noutral	2215	2500	12	42 F	47.7	F.C. 7	26.7	12.2	10.0	F2 2	46 F	11.0	10.7	21.4	22.2
Asian Paints	Neutral	2215	2500	13	42.5	47.7	56.7	-26.7	12.3	18.8	52.2	46.5	11.0	10.7	21.4	23.3
Britannia	Neutral	5569	5850	5	91.9	102.8	116.3	3.6	11.9	13.1	60.6	54.2	30.8	27.0	53.4	53.1
Colgate	Neutral	2374	2650	12	51.4	56.5	60.7	4.4	10.0	7.3	46.2	42.0	38.8	37.9	79.0	91.2
Dabur	Buy	467	575	23	10.2	11.3	12.4	-4.0	10.8	10.4	45.9	41.5	7.7	7.1	17.4	17.8
Emami Codrai Corra	Buy	572	750	31	20.3	21.7	23.4	12.4	7.2	7.6	28.2	26.3	9.3	8.1	34.4	32.9
Godrej Cons.	Buy	1189	1450	22	18.5	23.7	27.1	-4.3	27.9	14.3	64.2	50.2	10.1	9.5	15.4	19.6
HUL	Buy	2319	2850	23	44.3	47.8	52.3	1.4	7.8	9.5	52.3	48.5	11.0	10.7	20.7	22.4
ITC	Buy	414	525	27	16.0	17.2	18.6	-2.5	7.7	8.0	25.9	24.1	7.4	7.1	27.7	30.1
Indigo Paints	Buy	1090	1350	24	29.8	32.9	38.5	-3.8	10.4	17.1	36.6	33.1	5.0	4.5	14.7	14.4
Jyothy Lab	Neutral	337	375	11	10.2	11.1	12.2	4.0	8.5	10.1	33.0	30.4	6.0	5.8	19.4	19.5
L T Foods	Buy	459	470	2	17.4	22.5	28.0	2.0	29.0	24.6	26.3	20.4	4.1	3.6	16.8	18.8
Marico	Buy	691	800	16	12.4	14.3	15.4	7.9	15.2	7.9	55.8	48.4	22.4	21.2	40.9	45.0
Nestle	Neutral	2377	2400	1	32.0	36.8	41.0	-22.1	15.2	11.3	74.3	64.5	57.1	48.5	83.9	81.4
Page Inds	Buy	46188	57500	24	652.9	749.1	877.2	27.9	14.7	17.1	70.7	61.7	36.6	30.2	51.8	48.9
Pidilite Ind.	Neutral	3010	3000	0	41.3	46.7	53.5	16.7	13.0	14.7	72.9	64.5	15.7	14.0	23.1	22.9
P&G Hygiene	Neutral	13450	15000	12	246.5	273.0	300.0	11.9	10.8	9.9	54.6	49.3	46.7	39.2	93.7	86.7





Company   Reco   IMN   West   Develope   P725   P726   P			CMP	TP	% Upside		EPS (INR	)	EPS (	Gr. YoY	(%)	P/E	(x)	P/E	(x)	ROE	(%)
Tark Chemmer Row 1078 1960 266 140 170 170 170 170 170 170 170 170 170 17	Company	Reco			•		•	•					• •		• •		• •
United Spring   Neutral   2049   2000   2   17,7   27,2   36,5   31,6   33,8   34,   16,0   75,4   64,9   13,6   14,2   10,9   13,6   14,2   10,9   13,6   14,2   13,6   14,2   13,6   14,2   13,6   14,2	Radico Khaitan	Buy	2607	3000	15	25.8	36.7	46.3	34.9	42.1	26.2	101.1	71.1	13.0	11.3	12.8	15.9
United Springs   Neutral   1452   1566   14   19.8   22.4   25.0   25.8   31.1   17.   73.4   61.9   13.4   13.1   18.2   17.0   17.0   17.0   17.0   18.2   17.0   17.0   17.0   17.0   17.0   18.2   17.0	Tata Consumer	Buy	1078	1360	26	14.0	17.0	20.0	-2.4	21.7	17.4	77.0	63.3	5.3	4.7	7.7	8.2
Varung Reverages   May   470   665   42   77,   10,4   12,2   26,2   35,4   17,1   51,2   43,6   45,5   19,6   42,0   19,6   43,6   4	United Brew	Neutral	2049	2000	-2	17.7	27.2	36.5	13.6	53.8	34.4	116.0	75.4	12.4	11.4	10.9	15.8
Consumer	United Spirits	Neutral	1452	1650	14	19.8	22.4	25.0	25.8	13.1	11.7	73.4	64.9	13.4	11.1	18.2	17.1
Companish   Comp	Varun Beverages	Buy	470	665	42	7.7	10.4	12.2	26.2	35.4	17.1	61.2	45.2	9.6	8.2	22.0	19.6
Device   Hewells India   Sel   1700   10   23.5   37.6   34.0   10.2   15.7   17.5   23.3   65.7   56.9   16.1   10.2   17.5   13.0   18.0   19.0	Aggregate								-1.6	12.4	11.5	47.8	42.5	11.2	10.5	23.4	24.7
Hevelsindinging Neutral 1541 1700 10 23.5 27.6 34.0 15.7 17.5 23.3 65.7 55.9 11.6 10.7 18.3 KEI industring Neutral 3670 3500 -5 72.9 84.0 100.0 13.2 15.3 18.0 18.0 13.0 56.5 14.0 15.0 13.0 Polycab india Buy 6055 7250 20 21.34.3 153.1 181.8 181.1 13.1 14.0 18.7 44.9 39.4 97.6 27.8 26.0 13.0 Polycab india Buy 107 1600 25 25.4 31.0 38.9 215.2 12.0 25.6 10.0 19.0 14.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18																	
KEI Industries   Neutral   3670   3500   -5   72,9   34,0   100.   13.2   15.3   19.0   50.4   3.7   6.1   5.4   5.0   19.0   50.0   19		Neutral	1541	1700	10	23.5	27.6	34.0	15.7	17.5	23.3	65.7	55.9	11.6	10.2	17.7	18.3
Polyclationida		Neutral	3670	3500												15.6	
R R Kabel Neutral 162 1230 1230 1240 275 344 40.9 45.																	
Voltage   Volt		•															
Magnegate   Series																	
Marche Enterp.   Buy   6464   7600   18   72.0   10.4   160.3   8.6   45.0   5.5   8.8   61.9   9.0   7.7   10.9   16.0							02.0										
Amber Enterp.  Buy  6464  7600  18  77.0  10.1																	
Avalon Tech Buy 833 1030 24 9.6 16.1 25.2 125.2 67.4 57.2 86.8 51.9 9.0 7.7 10.9 16.0 Cylent DIM Buy 462 600 30 93. 15.2 22.0 28.8 63.6 445 45.5 80.3 3.9 34.8 10.5 17.0 16.0 16.0 16.0 16.0 16.0 16.0 16.0 16		Buv	6464	7600	18	72.0	104.4	160.3	82.6	45.0	53.5	89.8	61.9	9.6	8.3	11.2	14.3
Cypint DLM         Buy         462         600         30         9.3         15.2         21.0         20.8         63.6         44.5         49.5         49.5         30.3         3.9         3.4         8.0         12.0           Data Pattern         Neutral         3003         2530         -16         39.6         49.7         61.6         50.5         21.8         67.8         60.4         32.1         22.0         20.0         40.0         43.2         12.0         43.0         12.0         17.0         19.0         12.0         57.6         50.9         41.0         25.0         10.0         10.0         12.0         10.0         12.0	•	•															
Data Pattern Neutral 3003 2530 -16 39.6 49.7 63.9 22.1 25.5 28.6 75.8 60.4 11.1 94 15.7 16.9 Dixon Tech. Buy 14315 20500 43 117.2 16.87 241.6 90.5 44.0 43.2 122.2 84.9 28.7 21.7 30.0 29.1 Kasynes Tech Buy 543 7300 33 45.8 83.5 132.4 596 82.4 58.5 119.5 65.5 12.3 10.4 10.0 29.1 Kasynes Scheth. Buy 523 630 20 9.7 14.6 20.7 57.6 50.9 41.9 54.2 15.5 12.5 16.5 12.3 10.4 10.2 13.9 Aggregate		•															
Dixon Tech.    Buy	•	•															
Kaynes Tech Buy 547 7300 33 45.8 83.5 132.4 56.6 82.4 58.5 19.5 65.5 12.3 10.4 17.0 17.2 Syrma SGS Tech Buy 523 630 20 9.7 14.6 20.7 57.6 50.9 41.9 54.2 35.9 5.3 4.7 10.2 13.9 Aggregate  ***********************************																	
Syrma SGS Tech         Buy         523         630         20         9.7         14.6         20.7         57.6         50.9         41.9         54.2         59.5         4.7         10.2         11.5         17.2           Aggregate         Segregate         Segrega		•															
Aggregate																	
Healthcare  Alembic Phar Neutral 999 930 7 29.1 36.5 44.0 7.4 25.2 20.5 34.3 27.4 3.8 3.4 11.5 12.9 12.6 Alembic Phar Neutral 8488 4950 2 181.1 197.9 190.3 13.4 9.2 -3.8 26.8 24.5 4.8 4.2 19.4 18.5 Ajanta Pharma Buy 2636 3260 24 74.1 80.9 96.0 18.9 9.3 18.6 35.6 32.6 8.8 7.3 25.5 24.3 Apollo Hospitals Buy 693 8050 15 100.6 121.0 153.2 61.1 20.3 26.6 69.5 57.8 11.8 9.9 19.1 19.2 Aurobindo Buy 1151 1370 19 61.0 72.6 83.5 7.9 19.0 15.0 18.9 15.8 20 1.8 11.3 12.2 Elicoron Buy 355 400 13 2.0 4.5 9.2 13.2 119.9 104.5 174.0 79.1 2.0 1.9 12.2 51.0 Elius Jet Health Buy 954 965 1 17.6 22.1 27.6 78.5 15.2 24.4 24.0 51.4 51.4 10.0 19.2 Clpla Neutral 1505 1510 0 62.8 59.2 65.5 19.6 5.7 10.7 24.0 25.4 33.3 14.6 11.1 30.9 29.2 Clpla Neutral 6670 6540 -2 81.2 101.0 125.4 35.3 24.4 24.2 82.0 60.0 11.8 10.5 15.1 16.9 Dr Reddy's Neutral 1611 1220 -10 67.3 70.3 65.6 61.0 14.4 67.0 20.2 19.4 34.2 91.3 14.5 11.1 10.0 Pr Reddy's Neutral 1611 1220 -10 67.3 70.3 65.6 61.0 14.4 67.0 20.1 14.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 12.4 47.4 40.8 70.1 14.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 12.4 47.4 40.8 70.1 41.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 12.4 47.4 40.8 70.1 41.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 12.4 14.4 67.0 14.7 58.7 53.4 14.5 14.0 14.7 58.7 53.4 14.5 14.7 14.7 58.7 53.4 14.5 14.7 14.7 14.7 14.7 14.7 14.7 14.7 14.7	•	Биу	323	030	20	5.7	14.0	20.7									
Allembic Phar Neutral 999 930 -7 29.1 36.5 44.0 -7.4 25.2 20.5 34.3 27.4 3.8 3.4 11.5 12.9 Alkem Lab Neutral 4848 4950 2 181.1 197.9 190.3 13.4 9.2 -3.8 26.8 24.5 4.8 4.2 19.4 18.5 Ajanta Pharma Buy 2636 3260 24 74.1 80.9 96.0 18.9 97.0 18.0 18.6 18.5 18.6 18.5 18.6 18.6 18.6 18.6 18.6 18.6 18.6 18.6									00.0	30.3	40.5	101.1	07.2	13.0	11.5	13.7	17.2
Alkem Lab Neutral 4848 4950 2 181.1 197.9 190.3 13.4 9.2 -3.8 26.8 24.5 4.8 4.2 19.4 18.5 Ajanta Pharma Buy 2636 3260 24 74.1 80.9 190.3 18.6 18.5 36.6 26.6 36.8 36.8 36.8 24.5 24.3 Apollo Hospitals Buy 6993 8050 15 100.6 121.0 153.2 61.1 20.3 18.6 18.6 18.5 57.8 11.8 19.9 19.2 19.2 Apollo Hospitals Buy 1151 1370 19 61.0 72.6 83.5 7.9 190 104.5 18.0 18.9 18.5 57.8 11.8 10.3 12.2 19.0 19.0 19.0 19.0 19.0 19.0 19.0 19.0		Neutral	999	030	-7	20 1	36.5	44.0	-7 <i>1</i>	25.2	20.5	2/1 2	27.4	3 8	2 /	11 5	12 0
Ajanta Pharma Buy 2636 3260 24 74.1 80.9 96.0 18.9 9.3 18.6 35.6 32.6 32.6 32.5 24.3 Apollo Hospitals Buy 693 8050 15 100.6 12.0 153.2 61.1 20.3 26.6 69.5 57.8 11.8 9.9 19.1 19.2 Aurobindo Buy 1151 1370 19 61.0 72.6 83.5 7.9 19.0 15.0 16.0 15.0 15.0 15.0 19.2 12.5 Blue Jet Health Buy 355 400 13 2.0 4.5 21.2 17.6 78.5 17.0 19.0 15.0 10.4 51.0 19.1 19.0 12.0 19.2 Cipla Neutral 1505 1510 0 62.8 59.2 65.5 19.6 -5.7 10.7 24.0 25.4 33. 14.6 11.1 30.9 29.2 Cipla Neutral 1505 1510 0 66.8 8.2 1.0 10.0 12.5 15.0 12.5 15.0 10.0 12.5 15.																	
Apollo Hospitals Buy 6993 8050 15 100.6 121.0 153.2 61.1 20.3 26.6 69.5 7.8 11.8 9.9 19.1 19.2 Aurobindo Buy 1151 1370 19 61.0 72.6 83.5 7.9 19.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15																	
Aurobindo Buy 1151 1370 19 61.0 72.6 83.5 7.9 19.0 15.0 18.9 15.8 2.0 1.8 11.3 12.2 Biocon Buy 355 400 13 2.0 4.5 9.2 13.2 11.99 104.5 174.0 79.1 2.0 1.9 1.2 2.5 Blue Jet Health Buy 954 965 1 17.6 22.1 27.6 78.5 2.4 24.9 54.2 43.3 14.6 11.1 30.9 29.2 Cipla Neutral 6670 6540 -2 81.2 101.0 125.4 35.3 14.6 11.8 10.5 15.1 16.9 Drivis Lab Neutral 6670 6540 -2 81.2 101.0 125.4 35.3 24.4 24.2 82.2 66.0 11.8 10.5 15.1 16.9 Dr Agarwal's Hea Buy 375 460 23 2.6 3.8 5.1 0.0 44.2 34.0 14.7 98.3 6.3 5.9 5.2 16.2 EIRIS Lifescience Neutral 1361 1220 -10 67.3 70.3 65.6 6.1 4.4 4.4 4.4 4.0 14.7 98.3 6.3 5.9 5.2 16.2 EIRIS Lifescience Neutral 1361 1270 -2 82.5 12.6 37.8 53.1 12.4 47.4 40.8 70.1 47.5 8.6 7.5 12.9 16.9 Gland Pharma Buy 1670 1690 1 47.7 58.7 32.2 18.2 10.0 44.2 34.0 14.7 98.3 6.3 5.3 4.5 16.1 17.6 Gland Pharma Buy 1670 1690 1 47.7 58.7 32.2 18.2 10.2 14.3 12.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14	•																
Bilocon Buy 355 400 13 2.0 4.5 9.2 13.2 11.9 104.5 17.0 79.1 2.0 1.9 1.2 2.5 Blue Jet Health Buy 954 965 1 17.6 22.1 27.6 78.5 25.4 24.9 54.2 34.3 14.6 11.1 30.9 29.2 Cipla Neutral 1505 1510 0 62.8 59.2 55.5 19.6 -5.7 10.7 24.0 25.4 3.9 3.4 16.2 13.4 Divis Lab Neutral 6670 6540 -2 81.2 10.0 12.5 15.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 10.0 12.5 12.0 12.0 12.0 12.0 12.0 12.0 12.0 12.0	· · · · · · · · · · · · · · · · · · ·	•															
Blue   Jet   Health   Buy   954   965   1   17.6   22.1   27.6   78.5   25.4   24.9   54.2   33.3   14.6   11.1   30.9   29.2   20.5		•															
Cipla Neutral 1505 1510 0 62.8 59.2 65.5 19.6 -5.7 10.7 24.0 25.4 3.9 3.4 16.2 13.4 Divis Lab Neutral 6670 6540 -2 81.2 101.0 125.4 35.3 24.4 24.2 82.2 66.0 11.8 10.5 15.1 16.9 Dr Reddy's Neutral 1361 1220 -10 67.3 70.3 65.6 6.1 4.4 -6.7 20.2 19.4 3.4 2.9 18.2 16.1 Dr Agarwal's Hea Buy 375 460 23 2.6 3.8 5.1 0.0 44.2 34.0 141.7 98.3 6.3 5.9 5.2 6.2 ERIS Liffescience Neutral 1794 1350 -25 25.6 37.8 53.1 -12.4 47.4 40.8 70.1 47.5 8.6 7.5 12.9 16.9 Gland Pharma Buy 1689 1740 3 42.4 51.3 62.0 -10.9 21.1 20.8 39. 32.9 30. 2.8 7.8 8.8 Glenmark Buy 1670 1690 1 47.7 58.7 73.2 18.21 23.0 24.7 35.0 24.8 53. 45.5 16.1 7.2 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 16.1 72.6 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 16.1 Granules India Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 44. 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 16.2 58.8 15.1 20.5 44.8 22.3 22.6 38.0 31.1 5.0 44. 13.7 15.0 Laurus Labs Buy 232 2910 22 49.2 48.5 65.7 2.4 17.6 73.8 17.9 23.8 45.1 45.9 45.9 Harma Buy 238 2910 22 48.5 65.7 2.4 17.6 73.8 17.9 23.8 53. 42.2 20.8 17.1 13.3 Max Healthcare Buy 1333 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 18.6 60.1 11.3 9.7 14.8 17.4 17.9 17.9 18.9 18.9 18.9 18.9 18.9 18.9 18.9 18																	
Divis Lab Neutral 6670 6540 -2 81.2 101.0 125.4 35.3 24.4 24.2 82.2 66.0 11.8 10.5 15.1 16.9 Pr Reddy's Neutral 1361 1220 -10 67.3 70.3 65.6 6.1 4.4 -6.7 20.2 19.4 3.4 2.9 18.2 16.1 Dr Agarwal's Hea Buy 375 460 23 2.6 3.8 5.1 0.0 44.2 34.0 141.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 -12.4 47.4 40.8 70.1 47.5 8.6 7.5 12.9 16.9 Gland Pharma Buy 1689 1740 3 42.4 51.3 62.0 -10.9 21.1 20.8 39.8 32.9 30.0 2.8 7.8 8.8 Glenmark Buy 1670 1690 1 47.7 58.7 73.2 18.21 20.4 23.0 24.7 35.0 28.4 53.3 24.5 16.1 7.2 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 41.5 Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 81. 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1667 750 12 5.8 10.5 14.3 94.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 94.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 200 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 14.5 94.1 6.9 14.7 14.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 65.7 2.9 1.3 35.4 48.5 49.1 6.9 1.2 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 65.7 2.9 1.3 35.4 48.5 49.1 6.9 2.9 1.4 13.7 15.0 Sun Pharma Buy 200 250 25 0.7 12.2 2.7 62.5 70.6 12.9 29.0 17.0 6.2 15.6 4.9 17.0 17.0 17.0 17.0 17.0 17.0 17.0 17.0		•															
Dr Reddy's Neutral 1361 1220 -10 67.3 70.3 65.6 6.1 4.4 -6.7 20.2 19.4 3.4 2.9 18.2 16.1 Dr Agarwal's Hea Buy 375 460 23 2.6 3.8 5.1 0.0 44.2 34.0 141.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 -12.4 47.4 40.8 70.1 47.5 8.6 7.5 12.9 16.9 Gland Pharma Buy 1689 1740 3 42.4 51.3 62.0 -10.9 21.1 20.8 39.8 32.9 3.0 2.8 7.8 8.8 Glenmark Buy 1670 1690 1 47.7 58.7 73.2 1,821.0 23.0 24.7 35.0 28.4 5.3 4.5 16.1 17.2 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 41.5 Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 81. 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 21.0 3.3 2.9 13.0 28. 14.5 16.1 17.2 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 53.1 15.0 4.4 13.7 15.0 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 53.4 4.5 4.5 17.1 17.2 Lupin Neutral Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.0 6.1 13.3 9.7 14.8 17.4 Piramal Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.0 6.2 17.1 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 60.1 11.3 9.7 14.8 17.4 Piramal Pharma Buy 200 250 25 0.7 1.2 2.7 62.5 70.6 12.9 19.0 19.0 17.6 2.9 2.9 1.1 1.9 Sun Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 22.5 23.5 16.4 56.3 45.6 72.9 2.9 1.1 1.9 Sun Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 22.5 23.5 16.5 63.3 45.6 72. 21.5 4.1 3.5 21.2 17.5 Aggregate  Fighraphy 1329 1450 9 74.7 78.0 107.3 24.4 4.5 37.5 17.8 17.0 17.6 15.5 4.8 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5																	
Dr Agarwal's Hea Buy 375 460 23 2.6 3.8 5.1 0.0 44.2 34.0 141.7 98.3 6.3 5.9 5.2 6.2 ERIS Lifescience Neutral 1794 1350 -25 25.6 37.8 53.1 -12.4 47.4 40.8 70.1 47.5 8.6 7.5 12.9 16.9 Gland Pharma Buy 1689 1740 3 42.4 51.3 62.0 -10.9 21.1 20.8 39.8 32.9 3.0 2.8 7.8 8.8 Glenmark Buy 1670 1690 1 47.7 58.7 73.2 1,821.0 23.0 24.7 35.0 28.4 5.3 4.5 16.1 17.2 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 41.5 Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 8.1 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 92.4 80.6 36.2 114.9 63.6 7.8 7.1 7.2 11.7 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 5.3 4.2 20.8 19.7 Mankind Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.9 6.2 17.1 13.3 Mankind Pharma Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Buy 1689 2000 18 47.1 56.8 64.5 13.4 20.6 13.6 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 35.8 29.7 5.6 4.8 14.5 14.5 14.5 14.5 14.5																	
ERIS Lifescience         Neutral         1794         1350         -25         25.6         37.8         53.1         -12.4         47.4         40.8         70.1         47.5         8.6         7.5         12.9         16.9           Gland Pharma         Buy         1689         1740         3         42.4         51.3         62.0         -10.9         21.1         20.8         39.8         32.9         3.0         2.8         7.8         8.8           Glenmark         Buy         1670         1690         1         47.7         58.7         73.2         1,821.0         23.0         24.7         35.0         28.4         5.3         4.5         16.1         17.2           GSK Pharma         Neutral         3299         3040         -8         54.7         62.2         72.1         26.4         13.5         16.1         60.0         48.8         41.5         16.9         17.6         41.5 <td>· ·</td> <td></td>	· ·																
Gland Pharma         Buy         1689         1740         3         42.4         51.3         62.0         -10.9         21.1         20.8         39.8         32.9         3.0         2.8         7.8         8.8           Glenmark         Buy         1670         1690         1         47.7         58.7         73.2         1,821.0         23.0         24.7         35.0         28.4         5.3         4.5         16.1         17.2           GSK Pharma         Neutral         3299         3040         -8         54.7         62.2         72.1         26.4         13.5         16.1         60.3         53.1         28.6         22.0         47.5         41.5           Global Health         Buy         1187         1390         17         19.8         23.9         30.7         11.1         20.6         28.7         60.0         49.8         9.4         81.1         16.9         17.6           Granules India         Buy         509         600         18         19.7         24.3         31.3         13.6         23.3         28.9         25.9         21.0         33.2         2.9         13.8         44.7           IPCA Labs         Buy		•															
Glenmark Buy 1670 1690 1 47.7 58.7 73.2 1,821.0 23.0 24.7 35.0 28.4 5.3 4.5 16.1 17.2 GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 41.5 Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 8.1 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 92.4 80.6 36.2 114.9 63.6 7.8 7.1 7.2 11.7 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 5.3 4.2 20.8 19.7 Mankind Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.9 6.2 17.1 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 60.1 11.3 9.7 14.8 17.4 Piramal Pharma Buy 200 250 25 0.7 1.2 2.7 62.5 70.6 129.9 291.0 170.6 2.9 2.9 1.1 1.9 Sun Pharma Buy 1689 2000 18 47.1 56.8 64.5 13.4 20.6 13.6 35.8 29.7 5.6 4.9 16.6 17.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 45.6 7.2 6.0 27.1 28.9 Zydus Lifesciences Neutral 975 930 -5 46.0 45.4 42.5 22.3 -1.5 -6.3 21.2 21.5 4.1 3.5 21.2 17.5 Aggregate  G R Infraproject Buy 1329 1450 9 74.7 78.0 107.3 2.4 4.5 37.5 17.8 17.0 1.6 1.5 9.6 9.1 IRB Infra																	
GSK Pharma Neutral 3299 3040 -8 54.7 62.2 72.1 26.4 13.5 16.1 60.3 53.1 28.6 22.0 47.5 41.5 Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 8.1 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 92.4 80.6 36.2 114.9 63.6 7.8 7.1 7.2 11.7 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 5.3 4.2 20.8 19.7 Mankind Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.9 6.2 17.1 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 60.1 11.3 9.7 14.8 17.4 Piramal Pharma Buy 200 250 25 0.7 1.2 2.7 62.5 70.6 129.9 291.0 170.6 2.9 2.9 1.1 1.9 Sun Pharma Buy 1689 2000 18 47.1 56.8 64.5 13.4 20.6 13.6 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 45.6 7.2 6.0 27.1 28.9 Zydus Lifesciences Neutral 975 930 -5 46.0 45.4 42.5 22.3 -1.5 -6.3 21.2 21.5 4.1 3.5 21.2 17.5 Aggregate  GR Infraproject Buy 1329 1450 9 74.7 78.0 107.3 2.4 4.5 37.5 17.8 17.0 1.6 1.5 9.6 9.1 IRB Infra		•															
Global Health Buy 1187 1390 17 19.8 23.9 30.7 11.1 20.6 28.7 60.0 49.8 9.4 8.1 16.9 17.6 Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 92.4 80.6 36.2 114.9 63.6 7.8 7.1 7.2 11.7 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 5.3 4.2 20.8 19.7 Mankind Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.9 6.2 17.1 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 60.1 11.3 9.7 14.8 17.4 Piramal Pharma Buy 200 250 25 0.7 1.2 2.7 62.5 70.6 129.9 291.0 170.6 2.9 2.9 1.1 1.9 Sun Pharma Buy 1689 2000 18 47.1 56.8 64.5 13.4 20.6 13.6 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 45.6 7.2 6.0 27.1 28.9 Zydus Lifesciences Neutral 975 930 -5 46.0 45.4 42.5 22.3 -1.5 -6.3 21.2 21.5 4.1 3.5 21.2 17.5 Aggregate  GR Infraproject Buy 1329 1450 9 74.7 78.0 107.3 2.4 4.5 37.5 17.8 17.0 1.6 1.5 9.6 9.1 IRB Infra		•															
Granules India Buy 509 600 18 19.7 24.3 31.3 13.6 23.3 28.9 25.9 21.0 3.3 2.9 13.8 14.7 IPCA Labs Buy 1367 1750 28 36.0 44.0 53.9 44.8 22.3 22.6 38.0 31.1 5.0 4.4 13.7 15.0 Laurus Labs Buy 667 750 12 5.8 10.5 14.3 92.4 80.6 36.2 114.9 63.6 7.8 7.1 7.2 11.7 Lupin Neutral 2000 2200 10 71.6 84.2 90.3 72.4 17.6 7.3 27.9 23.8 5.3 4.2 20.8 19.7 Mankind Pharma Buy 2382 2910 22 49.2 48.5 65.7 2.9 -1.3 35.4 48.5 49.1 6.9 6.2 17.1 13.3 Max Healthcare Buy 1233 1350 9 15.1 20.5 24.5 10.0 35.9 19.3 81.6 60.1 11.3 9.7 14.8 17.4 Piramal Pharma Buy 200 250 25 0.7 1.2 2.7 62.5 70.6 129.9 291.0 170.6 2.9 2.9 1.1 1.9 Sun Pharma Buy 1689 2000 18 47.1 56.8 64.5 13.4 20.6 13.6 35.8 29.7 5.6 4.9 16.6 17.6 Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 45.6 7.2 6.0 27.1 28.9 Zydus Lifesciences Neutral 975 930 -5 46.0 45.4 42.5 22.3 -1.5 -6.3 21.2 21.5 4.1 3.5 21.2 17.5 Aggregate  GR Infraproject Buy 1329 1450 9 74.7 78.0 107.3 2.4 4.5 37.5 17.8 17.0 1.6 1.5 9.6 9.1 IRB Infra Neutral 50 50 50 0 1.1 2.2 2.6 11.7 98.2 17.9 44.7 22.6 1.5 1.4 4.0 6.6																	
IPCA Labs   Buy   1367   1750   28   36.0   44.0   53.9   44.8   22.3   22.6   38.0   31.1   5.0   4.4   13.7   15.0		•															
Laurus Labs       Buy       667       750       12       5.8       10.5       14.3       92.4       80.6       36.2       114.9       63.6       7.8       7.1       7.2       11.7         Lupin       Neutral       2000       2200       10       71.6       84.2       90.3       72.4       17.6       7.3       27.9       23.8       5.3       4.2       20.8       19.7         Mankind Pharma       Buy       2382       2910       22       49.2       48.5       65.7       2.9       -1.3       35.4       48.5       49.1       6.9       6.2       17.1       13.3         Max Healthcare       Buy       1233       1350       9       15.1       20.5       24.5       10.0       35.9       19.3       81.6       60.1       11.3       9.7       14.8       17.4         Piramal Pharma       Buy       200       25       25       0.7       1.2       2.7       62.5       70.6       129.9       291.0       170.6       2.9       2.9       1.1       1.9         Sun Pharma       Buy       1689       2000       18       47.1       56.8       64.5       13.4       20.6       13.6		•															
Lupin         Neutral         2000         2200         10         71.6         84.2         90.3         72.4         17.6         7.3         27.9         23.8         5.3         4.2         20.8         19.7           Mankind Pharma         Buy         2382         2910         22         49.2         48.5         65.7         2.9         -1.3         35.4         48.5         49.1         6.9         6.2         17.1         13.3           Max Healthcare         Buy         1233         1350         9         15.1         20.5         24.5         10.0         35.9         19.3         81.6         60.1         11.3         9.7         14.8         17.4           Piramal Pharma         Buy         200         250         25         0.7         1.2         2.7         62.5         70.6         129.9         291.0         170.6         2.9         2.9         1.1         1.9           Sun Pharma         Buy         1689         2000         18         47.1         56.8         64.5         13.4         20.6         13.6         35.8         29.7         5.6         4.9         16.6         17.6           Torrent Pharma         Neutral		•															
Mankind Pharma         Buy         2382         2910         22         49.2         48.5         65.7         2.9         -1.3         35.4         48.5         49.1         6.9         6.2         17.1         13.3           Max Healthcare         Buy         1233         1350         9         15.1         20.5         24.5         10.0         35.9         19.3         81.6         60.1         11.3         9.7         14.8         17.4           Piramal Pharma         Buy         200         250         25         0.7         1.2         2.7         62.5         70.6         129.9         291.0         170.6         2.9         2.9         1.1         1.9           Sun Pharma         Buy         1689         2000         18         47.1         56.8         64.5         13.4         20.6         13.6         35.8         29.7         5.6         4.9         16.6         17.6           Torrent Pharma         Neutral         3251         3430         6         57.8         71.3         90.2         22.7         23.5         26.4         56.3         45.6         7.2         6.0         27.1         28.9           Zydus Lifesciences         Neu																	
Max Healthcare         Buy         1233         1350         9         15.1         20.5         24.5         10.0         35.9         19.3         81.6         60.1         11.3         9.7         14.8         17.4           Piramal Pharma         Buy         200         250         25         0.7         1.2         2.7         62.5         70.6         129.9         291.0         170.6         2.9         2.9         1.1         1.9           Sun Pharma         Buy         1689         2000         18         47.1         56.8         64.5         13.4         20.6         13.6         35.8         29.7         5.6         4.9         16.6         17.6           Torrent Pharma         Neutral         3251         3430         6         57.8         71.3         90.2         22.7         23.5         26.4         56.3         45.6         7.2         6.0         27.1         28.9           Zydus Lifesciences         Neutral         975         930         -5         46.0         45.4         42.5         22.3         -1.5         -6.3         21.2         21.5         4.1         3.5         21.2         17.5           Aggregate	· · · · · · · · · · · · · · · · · · ·																
Piramal Pharma         Buy         200         250         25         0.7         1.2         2.7         62.5         70.6         129.9         291.0         170.6         2.9         2.9         1.1         1.9           Sun Pharma         Buy         1689         2000         18         47.1         56.8         64.5         13.4         20.6         13.6         35.8         29.7         5.6         4.9         16.6         17.6           Torrent Pharma         Neutral         3251         3430         6         57.8         71.3         90.2         22.7         23.5         26.4         56.3         45.6         7.2         6.0         27.1         28.9           Zydus Lifesciences         Neutral         975         930         -5         46.0         45.4         42.5         22.3         -1.5         -6.3         21.2         21.5         4.1         3.5         21.2         17.5           Aggregate         21.1         14.4         14.0         37.8         33.0         5.5         4.8         14.5         14.5           Infrastructure           G R Infraproject         Buy         1329         1450         9		•															
Sun Pharma     Buy     1689     2000     18     47.1     56.8     64.5     13.4     20.6     13.6     35.8     29.7     5.6     4.9     16.6     17.6       Torrent Pharma     Neutral     3251     3430     6     57.8     71.3     90.2     22.7     23.5     26.4     56.3     45.6     7.2     6.0     27.1     28.9       Zydus Lifesciences     Neutral     975     930     -5     46.0     45.4     42.5     22.3     -1.5     -6.3     21.2     21.5     4.1     3.5     21.2     17.5       Aggregate       Infrastructure       G R Infraproject     Buy     1329     1450     9     74.7     78.0     107.3     2.4     4.5     37.5     17.8     17.0     1.6     1.5     9.6     9.1       IRB Infra     Neutral     50     50     0     1.1     2.2     2.6     11.7     98.2     17.9     44.7     22.6     1.5     1.4     4.0     6.6		•															
Torrent Pharma Neutral 3251 3430 6 57.8 71.3 90.2 22.7 23.5 26.4 56.3 45.6 7.2 6.0 27.1 28.9 Zydus Lifesciences Neutral 975 930 -5 46.0 45.4 42.5 22.3 -1.5 -6.3 21.2 21.5 4.1 3.5 21.2 17.5 Aggregate    Comparison of Comparison		•															
Zydus Lifesciences Neutral       975       930       -5       46.0       45.4       42.5       22.3       -1.5       -6.3       21.2       21.5       4.1       3.5       21.2       17.5         Aggregate       21.1       14.4       14.0       37.8       33.0       5.5       4.8       14.5       14.5         Infrastructure         G R Infraproject       Buy       1329       1450       9       74.7       78.0       107.3       2.4       4.5       37.5       17.8       17.0       1.6       1.5       9.6       9.1         IRB Infra       Neutral       50       50       0       1.1       2.2       2.6       11.7       98.2       17.9       44.7       22.6       1.5       1.4       4.0       6.6		•															
Aggregate     21.1     14.4     14.0     37.8     33.0     5.5     4.8     14.5     14.5       Infrastructure       G R Infraproject     Buy     1329     1450     9     74.7     78.0     107.3     2.4     4.5     37.5     17.8     17.0     1.6     1.5     9.6     9.1       IRB Infra     Neutral     50     50     0     1.1     2.2     2.6     11.7     98.2     17.9     44.7     22.6     1.5     1.4     4.0     6.6																	
Infrastructure           G R Infraproject         Buy         1329         1450         9         74.7         78.0         107.3         2.4         4.5         37.5         17.8         17.0         1.6         1.5         9.6         9.1           IRB Infra         Neutral         50         50         0         1.1         2.2         2.6         11.7         98.2         17.9         44.7         22.6         1.5         1.4         4.0         6.6		Neutral	975	930	-5	46.0	45.4	42.5									
G R Infraproject Buy 1329 1450 9 74.7 78.0 107.3 2.4 4.5 37.5 17.8 17.0 1.6 1.5 9.6 9.1 IRB Infra Neutral 50 50 0 1.1 2.2 2.6 11.7 98.2 17.9 44.7 22.6 1.5 1.4 4.0 6.6	Aggregate								21.1	14.4	14.0	37.8	33.0	5.5	4.8	14.5	14.5
IRB Infra Neutral 50 50 0 1.1 2.2 2.6 11.7 98.2 17.9 44.7 22.6 1.5 1.4 4.0 6.6	Infrastructure																
		•															
KNR Constructions Neutral 216 210 -3 14.0 10.8 14.2 -8.1 -22.7 30.9 15.4 19.9 1.5 1.4 11.0 7.4	IRB Infra		50	50	0							44.7			1.4	4.0	6.6
	KNR Constructions	Neutral	216	210	-3	14.0	10.8	14.2	-8.1	-22.7	30.9	15.4	19.9	1.5	1.4	11.0	7.4







		CMP	TP	% Upside		EPS (INR	*	EPS	Gr. YoY	• •		(x)	P/B	• •		(%)
Company	Reco	(INR)	(INR)	Downside	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY25E	FY26E				FY26E
Aggregate											27.7	20.7	1.6	1.5	5.7	7.1
Logistics																
Adani Ports	Buy	1405	1700	21	50.2	63.2	73.4	21.6	26.0	16.1	28.0	22.2	4.9	4.1	18.8	20.0
Blue Dart Express	Buy	6300	7600	21	103.1	145.7	191.0	-15.2	41.4	31.1	61.1	43.2	9.2	7.8	16.0	19.6
Concor	Buy	761	850	12	21.3	26.7	30.5	4.9	25.3	14.4	35.8	28.5	3.8	3.5	10.7	12.7
JSW Infra	Buy	303	370	22	7.0	7.5	9.4	20.5	7.8	25.3	43.4	40.3	6.5	5.8	16.3	15.4
Mahindra Logistics	Neutral	339	300	-11	-5.0	14.2	26.7	-38.8	LP	87.7	NM	23.8	5.5	4.6	-7.5	20.6
Transport Corp.	Buy	1116	1330	19	53.5	57.5	66.6	16.8	7.4	15.9	20.9	19.4	4.0	3.4	19.5	18.6
TCI Express	Neutral	755	710	-6	22.4	30.1	35.3	-34.8	34.6	17.0	33.7	25.1	3.8	3.4	11.7	14.3
VRL Logistics	Buy	564	710	26	20.9	27.9	29.6	106.5	33.4	6.2	27.0	20.2	4.5	4.1	18.0	21.4
Aggregate											31.5	25.2	5.0	4.3	16.0	17.2
Media																
PVR Inox	Neutral	956	1050	10	-15.4	9.8	22.4	-232.4	LP	127.7	NM	97.3	1.3	1.3	-2.1	1.4
Sun TV	Neutral	620	630	2	43.4	45.5	48.3	-8.8	4.9	6.0	14.3	13.6	2.1	1.9	15.0	14.3
Zee Ent.	Neutral	137	125	-9	8.2	9.2	10.4	80.8	12.0	13.7	16.8	15.0	1.1	1.1	7.0	7.4
Aggregate								-3.3	18.2	12.7	20.2	17.1	1.6	1.5	7.8	8.7
Metals																
Coal India	Buy	391	480	23	57.4	60.4	69.1	-5.5	5.3	14.4	6.8	6.5	2.4	2.1	35.7	31.8
Hindalco	Buy	642	790	23	74.8	69.5	73.7	63.9	-7.1	6.0	8.6	9.2	1.5	1.3	18.8	14.9
Hind. Zinc	Neutral	514	460	-11	24.7	31.2	32.0	34.5	26.3	2.7	20.8	16.5	16.3	10.1	73.2	75.8
JSPL	Buy	921	1100	19	41.4	59.2	93.1	-29.1	43.0	57.3	22.2	15.5	2.0	1.8	9.1	12.0
JSW Steel	Buy	987	1190	21	15.6	49.4	78.0	-57.7	217.5	57.9	63.4	20.0	3.0	2.7	4.8	14.2
Jindal Stainless	Buy	712	770	8	30.5	36.2	44.5	-3.9	18.7	22.7	23.4	19.7	3.5	3.0	15.1	15.4
Nalco	Neutral	186	200	8	28.7	18.5	21.0	215.8	-35.6	13.6	6.5	10.1	1.9	1.7	32.7	17.7
NMDC	Buy	70	83	18	7.4	8.4	9.4	13.1	12.3	12.0	9.5	8.4	2.1	1.8	23.6	22.9
SAIL	Neutral	129	145	12	3.2	7.2	13.5	24.3	123	87.4	39.9	17.9	0.9	0.9	2.3	5.0
Tata Steel	Neutral	152	155	2	3.4	9.9	13.9	41.5	194	41.1	45.2	15.4	2.2	2.1	4.9	14.2
Vedanta	Neutral	458	470	3	34.8	41.8	47.6	162.2	20	13.8	13.2	10.9	4.3	3.6	37.0	36.2
Aggregate								16.4	24.5	22.5	14.7	11.8	2.5	2.2	16.8	18.5
Oil & Gas																
Aegis Logistics	Neutral	790	715	-9	14.8	20.0	20.4	-9.0	35.3	2.1	53.5	39.6	6.6	5.9	12.7	15.7
BPCL	Neutral	313	300	-4	31.8	27.8	28.3	-49.7	-12.8	2.0	9.8	11.3	1.6	1.5	17.3	13.9
Castrol India	Buy	212	250	18	9.4	9.5	10.0	7.3	1.7	4.8	22.6	22.2	9.2	8.5	42.1	39.8
GAIL	Buy	191	212	11	14.4	15.5	17.1	4.8	8.0	10.0	13.3	12.3	1.7	1.5	9.5	13.8
Gujarat Gas	Buy	470	535	14	16.6	17.9	21.1	4.0	7.6	17.7	28.2	26.2	3.8	3.5	14.2	13.9
Gujarat St. Pet.	Neutral	331	356	7	14.3	11.2	11.8	-37.1	-22.0	5.2	23.1	29.7	1.7	1.7	7.7	5.7
HPCL	Buy	387	455	18	31.6	44.0	44.2	-57.9	39.0	0.5	12.2	8.8	1.6	1.4	13.7	17.3
IOC	Buy	140	165	17	7.8	10.3	10.9	-73.6	32.5	6.0	18.1	13.7	1.0	1.0	5.8	7.4
IGL	Buy	199	230	16	10.5	10.9	12.4	-16.0	4.4	13.6	19.0	18.2	3.0	2.7	16.5	15.7
Mahanagar Gas	Buy	1346	1760	31	105.8	111.5	121.0	-18.9	5.4	8.5	12.7	12.1	2.3	2.0	18.9	17.7
MRPL	Sell	139	105	-24	0.3	11.4	11.5	-98.6	3,840.0	1.2	481.7	12.2	1.9	1.7	0.4	14.5
Oil India	Buy	478	495	4	37.6	41.7	44.9	-22.7	11.0	7.5	12.7	11.5	1.7	1.6	13.7	14.2
ONGC	Buy	251	280	11	30.6	32.4	36.0	-31.9	5.9	11.4	8.2	7.8	0.9	0.9	11.3	11.4
PLNG	Neutral	301	315	5	26.2	28.4	31.2	11.0	8.4	9.9	11.5	10.6	2.3	2.1	21.6	20.6
Reliance Ind.	Buy	1428	1515	6	51.5	59.5	66.5	0.0	15.6	11.7	27.7	24.0	4.6	2.1	8.5	9.2
Aggregate								-31.8	13.1	9.6	18.8	16.6	1.8	1.7	9.7	10.1
Real Estate																
Anant Raj	Buy	545	1085	99	12.4	17.9	20.8	59.4	44.6	15.8	43.9	30.4	4.5	3.9	10.2	12.9
Brigade Enterpr.	Buy	1186	1583	33	33.6	44.9	64.2	51.9	34.0	42.7	35.3	26.4	4.3	3.7	15.0	15.1
DLF	Buy	852	967	14	17.6	17.8	13.4	60.3	0.9	-24.8	48.3	47.8	3.6	3.3	10.7	9.9
Godrej Propert.	Buy	2405	2755	15	50.0	89.2	86.7	86.0	78.4	-2.8	48.1	27.0	3.9	3.4	10.2	13.4
Kolte Patil Dev.	Buy	456	560	23	14.1	47.9	43.6	-253.7	240.5	-9.0	32.4	9.5	4.2	2.9	13.6	35.9
Oberoi Realty	Neutral	1900	1726	-9	61.2	79.2	96.7	15.5	29.5	22.1	31.0	24.0	4.4	3.8	15.1	16.9
Macrotech Devel.	Buy	1453	1625	12	28.7	36.6	36.7	70.4	27.7	0.4	50.7	39.7	6.9	6.0	14.6	16.2





		CNAD	TD	0/ 11mc!-l		EDC (INC	١	EDC	Cr V-V	10/1	p/=	(14)	D/5	0 (1/1)	DO:	: (0/)
Company	Reco	CMP (INR)	TP (INR)	% Upside Downside		FY26E	FY27E	FY24	Gr. YoY		P/E FY25E	• •		FY26F		FY26F
Lifespace	Reco	(IIVK)	(IIVK)	Downside	FIZJE	F120E	FIZZE	F124	FIZJE	FIZUE	FIZJE	FIZUE	FIZJE	FIZUE	FIZJE	FIZUE
SignatureGlobal	Buy	1287	1760	37	7.2	55.7	125.3	511.9	674.8	12/17	178.9	23.1	24.9	12.0	14.9	70.0
Sunteck Realty	Buy	447	540	21	10.3	12.2	26.1	111.9	18.4	114.8		36.8	2.0	1.9	4.7	5.3
Sobha	Buy	1563	1778	14	8.9	33.7	50.6	71.0	281.0	49.9	176.5	46.3	3.7	3.4	2.7	7.6
Prestige Estates	Buy	1655	1938	17	13.6	22.6	25.9	-28.2	65.7	14.7	121.6	73.4	4.0	3.8	3.8	5.3
Phoenix Mills	Neutral	1596	1672	5	27.5	43.8	59.0	-10.6	58.9	34.7	58.0	36.5	5.5	4.8	9.9	14.0
Aggregate								42.8	36.9	11.5	52.1	38.0	5.1	4.5	9.7	11.9
Retail																
Aditya Birla Fashion	Neutral	74	100	35	-4.1	-1.7	-0.4	-33.1	Loss	Loss	NM	NM	1.5	1.6	-10.4	-4.3
Avenue Supermarts	Buy	4051	4350	7	41.6	46.8	55.0	6.7	12.5	17.4	97.4	86.5	12.3	10.8	13.5	13.3
Barbeque-Nation	Neutral	329	325	-1	-6.9	-4.2	-1.5	142.4	Loss	Loss	NM	NM	3.5	3.7	-7.5	-4.7
Bata India	Neutral	1215	1200	-1	19.4	24.8	30.1	-14.7	27.6	21.2	62.5	49.0	9.9	9.0	16.1	19.3
Campus Activewe.	Buy	283	330	17	4.0	5.5	7.3	35.5	38.8	32.3	71.4	51.5	11.4	9.4	16.0	18.2
Devyani Intl.	Buy	166	210	27	0.2	0.9	1.5	-75.7	385.4	69.2	885.8	182.5	18.3	27.7	2.1	12.1
Go Fashion (I)	Buy	840	1127	34	17.3	20.0	25.0	13.0	15.4	25.5	48.6	42.1	9.5	8.5	14.4	13.8
Jubilant Food.	Neutral	681	750	10	3.6	6.5	9.2	-9.6	83.2	40.6	190.8	104.1	21.4	20.9	11.2	20.0
Kalyan Jewellers	Buy	519	625	20	7.8	10.7	13.0	34.9	37.4	20.8	66.3	48.3	11.1	9.6	17.9	21.3
Metro Brands	Buy	1221	1400	15	13.9	16.5	20.0	9.4	18.4	21.4	87.6	74.0	19.0	16.2	21.2	24.2
P N Gadgil Jewellers	Buy	593	825	39	17.4	21.3	27.4	32.5	22.1	28.7	34.1	27.9	5.2	4.4	22.6	17.0
Raymond Lifestyle	Buy	1097	1500	37	16.5	48.8	68.7	-79.4	195.7	40.8	66.5	22.5	0.7	0.7	2.3	6.6
Restaurant Brand	Buy	79	135	71	-4.0	-2.4	-0.4	-6.7	Loss	Loss	NM	NM	5.1	6.1	-30.6	-16.7
Relaxo Footwear	Sell	422	375	-11	6.8	8.1	9.4	-15.0	17.9	16.3	61.6	52.2	5.0	4.7	8.3	9.2
Sapphire Foods	Buy	321	400	25	1.0	2.5	4.2	-38.9	154.5	64.0	322.3	126.6	7.4	7.0	2.3	5.7
Senco Gold	Neutral	348	400	15	12.4	14.2	16.7	6.2	14.6	18.0	28.1	24.5	2.9	2.6	12.1	11.2
Shoppers Stop	Neutral	504	500	-1	0.6	-0.8	-3.2	-88.9	PL	Loss	822.9	NM	16.3	12.7	2.0	-2.6
Titan Company	Buy	3424	4000	17	42.3	53.5	63.3	7.6	26.7	18.2	81.0	63.9	26.2	20.4	35.8	35.9
Trent	Buy	5589	6900	23	43.2	55.5	68.3	47.7	28.5	23.2	129.5	100.8	34.0	25.0	32.2	30.6
Vedant Fashions	Neutral	787	775	-1	16.0	17.5	19.5	-6.2	9.6	11.1	49.2	44.8	11.0	9.8	22.9	21.1
V-Mart Retail Westlife	Neutral Neutral	3652 716	3600 775	-1 8	0.8	64.4 4.5	92.8 7.6	-121.3 -82.4	518.8 475.3	69.8	350.7 914.7	56.7	8.2 18.5	7.0	2.6	9.4
Foodworld	Neutrai	710			0.0	4.5	7.0									
Aggregate								15.3	34.0	24.0	100.0	76.1	13.3	11.9	13.3	15.6
Technology																
Cyient	Sell	1304	1120	-14	55.4	74.6	83.2	-17.2	34.6	11.6	23.5	17.5	2.7	2.5	12.1	14.0
HCL Tech.	Buy	1695	1800	6	63.9	68.8	75.0	10.3	7.7	9.1	26.5	24.6	6.6	6.7	25.2	27.1
Hexaware Tech.	Buy	831	950	14	19.3	23.9	28.1	17.6	24.1	17.2	43.1	34.7	9.4	8.3	23.5	25.9
Infosys LTI Mindtree	Neutral Buy	1602 5426	1600 5150	-5	63.8 155.3	66.9 172.4	71.9 193.6	0.8	4.8 11.0	7.5 12.3	25.1 34.9	23.9 31.5	6.9 7.1	6.9	28.8	29.0
L&T Technology	Neutral	4442	4400	-5 -1	119.0	140.6	162.3	-3.2	18.1	15.4	37.3	31.6	7.7	6.7	22.0	22.6
Mphasis	Neutral	2645	2700	2	89.3	98.0	102.5	9.2	9.8	10.7	29.6	27.0	5.2	4.8	18.5	18.7
Coforge	Buy	1793	2200	23	25.0	46.3	58.1	-9.3	85.0	25.4	71.6	38.7	9.3	8.4	13.9	18.0
Persistent Sys	Buy	5885	6450	10	90.2	114.0	141.2	20.2	26.4	23.9	65.2	51.6	14.3	12.3	24.8	25.9
TCS	Buy	3447	3850	12	134.2	142.5	153.1	6.3	6.2	7.5	25.7	24.2	13.2	12.6	52.4	53.3
Tech Mah	Buy	1659	1950	18	47.9	60.9	77.0	17.1	27.0	26.5	34.6	27.2	5.4	5.2	15.7	19.5
Wipro	Sell	260	215	-17	12.5	12.1	12.6	22.8	-3.7	4.3	20.8	21.6	3.3	3.2	16.6	15.1
Zensar Tech	Neutral	867	740	-15	28.4	31.9	35.2	-2.5	12.3	10.5	30.5	27.2	4.8	4.5	17.0	17.2
Aggregate						-		8.7	7.1	9.0	26.9	25.1	7.6	7.3	28.1	29.2
Telecom																
Bharti Airtel	Buy	1842	2110	15	30.3	47.6	62.9	54.2	57.2	32.1	60.8	38.7	9.1	7.8	18.0	22.5
Bharti Hexacom	Neutral	1785	1900	6	25.6	38.3	55.5	58.7	49.6	44.8	69.7	46.6	15.0	12.1	24.2	28.9
Indus Towers	Neutral	381	395	4	18.4	25.6	29.8	-18.0	39.4	16.4	20.7	14.9	3.2	2.6	16.3	18.8
Vodafone Idea	Sell	7	7	-3	-3.8	-2.9	-2.9	-39.9	Loss	Loss	NM	NM	-0.3	-0.3	NM	NM
Tata Comm	Neutral	1703	1660	-3	28.7	52.6	69.7	-32.0	82.9	32.5	59.3	32.4	16.1	12.9	34.1	44





		СМР	TP	% Upside		EPS (INR	)	EPS	Gr. YoY	(%)	P/E	(x)	P/E	3 (x)	ROE	(%)
Company	Reco	(INR)	(INR)	Downside	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Aggregate								Loss	LP	235.0	-501	244	16.9	12.3	-3.4	5.0
Utilities																
Acme Solar	Buy	245	302	23	4.5	8.2	10.5	-563.2	80.8	28.6	54.3	30.0	3.3	3.0	7.7	10.4
Indian Energy Exchange	Neutral	187	209	12	4.7	5.1	5.9	21.4	10.5	14.7	40.2	36.4	15.2	13.0	40.5	38.5
JSW Energy	Buy	506	592	17	10.7	14.3	18.5	1.6	33.8	29.5	47.4	35.4	3.2	3.0	7.7	8.7
NTPC	Neutral	332	383	15	20.3	25.0	26.7	6.2	22.8	6.9	16.3	13.3	1.8	1.7	11.7	13.2
Power Grid Corpn	Buy	286	386	35	16.7	19.0	20.0	-0.3	14.1	4.8	17.1	15.0	2.9	2.7	17.3	18.4
Suzlon Energy	Buy	65	83	28	1.1	1.7	2.4	105.5	57.6	39.6	60.1	38.1	14.5	10.5	29.4	31.9
Tata Power Co.	Buy	397	476	20	12.3	15.5	17.1	11.7	26.6	10.0	32.4	25.6	3.5	3.1	11.5	13
Aggregate								6.9	21.9	9.3	22	18	2.7	2.5	12.6	14.0
Others																
APL Apollo Tubes	Buy	1846	1920	4	27.3	43.4	56.2	3.4	59.0	29.4	67.6	42.5	12.2	9.8	19.4	25.5
Cello World	Buy	600	720	20	15.3	17.1	22.0	-1.7	11.7	28.7	39.1	35.0	5.9	5.0	15.6	15.0
Coromandel Intl	Buy	2294	2600	13	61.3	78.0	92.8	9.8	27.3	19.0	37.5	29.4	6.1	5.2	17.6	19.1
Dreamfolks Services	Buy	272	350	29	11.9	16.5	20.9	-5.0	38.6	26.4	22.8	16.5	4.8	3.7	24.2	26.1
EPL	Buy	243	270	11	11.3	14.1	16.7	39.9	24.3	18.5	21.5	17.3	3.3	2.9	16.3	18.0
Eternal	Buy	249	260	4	0.6	1.0	3.2	44.2	78.2	201.4	423.7	237.8	7.4	7.2	2.1	3.1
Godrej Agrovet	Buy	787	840	7	22.4	29.5	37.6	19.5	31.6	27.6	35.2	26.7	6.3	8.3	17.5	27.0
Gravita India	Buy	1755	2300	31	42.3	55.4	74.1	22.2	30.9	33.7	41.5	31.7	6.3	5.2	21.5	18.0
Indiamart Inter.	Buy	2466	2650	7	91.7	81.7	94.6	66.1	-10.9	15.7	26.9	30.2	6.8	5.7	28.1	20.5
Indian Hotels	Buy	733	940	28	11.8	14.7	17.5	33.4	24.0	19.2	62.0	50.0	9.3	7.9	16.3	17.1
Info Edge	Neutral	1460	1350	-8	11.9	17.5	21.7	-7.4	46.8	23.9	122.5	83.5	3.4	3.3	2.7	4.0
Interglobe	Buy	5262	6375	21	188.1	253.5	265.7	-11.2	34.7	4.8	28.0	20.8	21.7	10.9	129.1	70.2
Kajaria Ceramics	Buy	1045	950	-9	21.8	23.4	27.4	-21.9	7.4	16.8	47.9	44.6	6.1	5.7	12.8	13.0
Lemon Tree Hotel	Buy	139	200	44	2.5	3.9	4.8	32.4	56.8	20.7	55.1	35.1	9.3	7.4	18.5	23.4
MTAR Tech	Buy	1682	1950	16	17.2	34.8	55.4	-5.8	102.5	59.0	97.8	48.3	7.1	6.2	7.5	13.7
One 97	Neutral	882	870	-1	-3.6	2.9	15.7	-83.9	LP	435.7	NM	300.7	4.3	4.4	-1.7	1.5
Quess Corp	Neutral	312	360	15	15.2	15.7	18.4	63.3	3.5	17.3	20.6	19.9	3.3	3.8	11.6	23.1
SBI Cards	Neutral	1007	975	-3	20.2	32.9	45.1	-20.5	63.2	36.9	49.9	30.6	7.0	5.7	14.8	20.6
SIS	Buy	370	400	8	21.5	32.2	38.0	65.6	49.7	18.0	17.2	11.5	1.1	0.9	13.2	17.6
Swiggy	Neutral	354	340	-4	-13.6	-18.3	-13.1	27.4	Loss	Loss	NM	NM	7.9	13.4	-34.6	-51.5
Team Lease Serv.	Buy	1978	2300	16	64.9	105.4	118.7	0.1	62.4	12.6	30.5	18.8	3.7	3.1	12.7	17.6
Time Technoplast	Buy	439	578	32	17.1	21.4	26.3	25.0	25.3	22.6	25.7	20.5	3.4	3.0	14.3	15.7
Updater Services	Buy	300	400	33	17.7	20.4	25.9	56.2	14.8	27.3	16.9	14.7	2.1	1.8	13.1	13.2
UPL	Neutral	633	660	4	25.0	39.7	57.5	583.6	58.8	44.7	25.3	15.9	1.1	1.0	7.1	10.1
· · · · · · · · · · · · · · · · · · ·	· ·			· ·												_





Index	1 Day (%)	1M (%)	12M (%)
Sensex	-0.7	0.0	5.6
Nifty-50	-0.7	0.6	5.6
Nifty Next 50	-0.8	2.9	-5.5
Nifty 100	-0.7	1.0	3.6
Nifty 200	-0.6	1.6	4.1
Company	1 Day (%)	1M (%)	12M (%)
Automobiles	-0.4	0.7	-8.1
Amara Raja Ener.	-0.4	-1.1	-25.2
Apollo Tyres	-1.1	-4.3	-5.2
Ashok Leyland	-0.2	1.9	-0.8
Bajaj Auto	-1.2	5.0	-14.7
Balkrishna Inds	-0.2	-8.6	-22.8
Bharat Forge	0.3	8.8	-20.0
Bosch	0.3	1.5	-2.6
CEAT	-1.3	-1.7	45.9
Craftsman Auto	0.4	2.4	19.5
Eicher Motors	0.1	-1.8	10.8
Endurance Tech.	-2.0	11.5	-6.0
Escorts Kubota	-1.2	-10.6	-26.3
Exide Inds.	-2.4	2.6	-29.0
Happy Forgings	-1.7	14.9	-21.3
Hero Motocorp	-0.7	6.6	-25.5
Hyundai Motor	-0.8	9.8	
M & M	-0.4	-1.6	5.0
CIE Automotive	-1.1	5.4	-21.8
Maruti Suzuki	0.1	-0.6	-3.4
MRF	0.5	-2.4	8.7
Sona BLW Precis.	-1.8	-1.2	-23.0
Motherson Sumi	-0.8	8.1	-8.7
Motherson Wiring	-0.3	8.0	-15.6
Tata Motors	-0.5	0.6	-27.8
TVS Motor Co.	0.1	1.1	12.3
Tube Investments	-1.4	-1.9	-30.7
Banks-Private	-0.9	0.5	11.5
AU Small Fin. Bank	-1.3	9.8	15.0
Axis Bank	-0.6	1.0	2.7
Bandhan Bank	-1.4	7.9	-9.8
DCB Bank	-0.7	1.6	5.7
Equitas Sma. Fin	-1.7	22.6	-31.7
Federal Bank	-0.6	3.6	19.2
HDFC Bank	-1.3	-0.3	21.3
ICICI Bank	-0.6	-1.0	27.9
IDFC First Bank	-0.6	2.1	-9.1
IndusInd Bank	-1.6	6.1	-45.8
Kotak Mah. Bank	-0.9	-0.4	22.1
RBL Bank	-1.2	6.0	-15.2
SBI Cards	0.5	13.5	38.5
Banks-PSU	-1.2	5.5	-6.6
ВОВ	-0.6	2.8	-15.4
Canara Bank	-3.6	6.4	-8.6
Indian Bank	0.0	7.6	15.3
Punjab Natl.Bank	-1.3	9.1	-15.8
St Bk of India	-1.7	-1.2	-6.1

Index	1 Day (%)	1M (%)	12M (%)
Nifty 500	-0.6	2.5	3.8
Nifty Midcap 100	-0.4	4.9	6.5
Nifty Smallcap 100	-0.5	8.7	2.6
Nifty Midcap 150	-0.4	5.2	4.7
Nifty Smallcap 250	-0.4	8.8	3.0
Union Bank (I)	-2.8	11.8	0.0
NBFCs	-0.9	0.5	18.1
Aditya Birla Capital Ltd	-0.5	10.0	-3.0
Bajaj Fin.	-0.7	-0.5	-20.3
Cholaman.Inv.&Fn	2.8	8.4	24.0
Can Fin Homes	-1.1	13.6	-60.0
CreditAcc. Gram.	-1.5	15.7	-0.7
Fusion Microfin.	-0.6	9.6	30.4
Five-Star Bus.Fi	-1.1	8.3	5.6
Home First Finan	-0.8	-0.5	-16.6
Indostar Capital	3.2	21.0	49.7
IIFL Finance	-1.3	8.6	-5.1
L&T Finance	-1.5	8.6	-7.1
LIC Housing Fin.	1.7	17.2	45.0
MCX	0.2	12.7	-7.5
M & M Fin. Serv.	-3.1	-3.4	26.8
Muthoot Finance	-0.6	0.2	-22.8
Manappuram Fin.	-1.5	8.7	-4.5
MAS Financial Serv.	-2.2	-1.4	-19.3
PNB Housing	1.8	5.1	-20.5
Power Fin.Corpn.	-1.3	-4.2	-64.6
REC Ltd	5.5	18.1	45.8
Repco Home Fin	-2.5	13.7	17.8
Shriram Finance	-1.5	14.4	2.2
Spandana Sphoort	-3.1	17.6	11.3
Nippon Life Ind.	0.9	25.4	57.9
UTI AMC	-1.2	10.5	24.3
Nuvama Wealth	1.2	15.3	67.8
Prudent Corp.	0.6	27.3	94.8
NBFC-Non Lending			
360 One	-1.1	17.3	0.5
Aditya AMC	-2.3	9.8	8.6
Anand Rathi Wea.	-0.1	4.3	14.8
Angel One	-1.8	-1.6	8.2
BSE	-1.0	0.9	-2.5
CDSL	-2.1	13.1	39.3
Cams Services	-2.1	11.8	-3.6
HDFC AMC	-1.6	11.2	197.3
KFin Technolog.	-0.4	3.2	27.9
MCX	0.2	12.7	-7.5
Nippon Life Ind.	0.9	25.4	57.9
Nuvama Wealth	1.2	15.3	67.8
Prudent Corp.	0.6	27.3	94.8
UTI AMC	-1.2	10.5	24.3
Insurance	2.2	2.4	26.6
HDFC Life Insur.	-0.2	2.4	26.8
ICICI Pru Life	-0.3	4.3	5.6
ICICI Lombard	2.0	4.0	16.7





Company	1 Day (%)	1M (%)	12M (%)
Life Insurance	-0.6	13.5	-6.4
Max Financial	0.8	18.3	54.5
Niva Bupa Health	-1.0	-4.0	
SBI Life Insuran	-0.6	0.9	21.1
Star Health Insu	-2.6	13.9	-14.2
Chemicals			
Alkyl Amines	-0.4	17.2	-1.5
Atul	-1.0	2.0	12.8
Clean Science	0.7	17.7	7.2
Deepak Nitrite	-1.1	-2.0	-20.8
Fine Organic	-1.3	10.3	0.9
Galaxy Surfact.	-0.7	7.5	-10.4
Navin Fluo.Intl.	0.3	4.9	27.6
NOCIL	-1.0	4.3	-26.2
P I Inds.	0.6	9.2	9.2
SRF	-0.2	5.9	29.2
Tata Chemicals	-0.8	10.6	-17.1
Vinati Organics	-0.1	9.6	0.6
Capital Goods	0.2	32.8	-3.8
A B B	-0.4	6.4	-29.0
Bharat Electron	1.8	17.4	31.0
Cummins India	-0.4	15.0	-10.8
Hind.Aeronautics	1.4	9.0	-10.8
Hitachi Energy	4.4	11.3	64.2
K E C Intl.	-1.2	19.5	0.8
Kalpataru Proj.	-0.5	15.6	-5.4
Kirloskar Oil	-1.7	22.6	-31.7
Larsen & Toubro	-0.5	0.6	-31.7
Siemens	-0.2	11.8	-11.3
Thermax	-0.2	6.8	-33.6
Triveni Turbine	-0.7	9.0	6.0
Zen Technologies	3.7	27.4	91.8
Cement	3.7	27.4	91.8
Ambuja Cem.	-1.1	1.0	-18.4
ACC	-1.0	-0.4	-30.0
Birla Corp.	-0.6	1.6	-12.5
Dalmia Bhar.	-0.7	4.1	9.9
Grasim Inds.	-0.9	-1.7	8.4
India Cem	0.3	4.7	52.2
J K Cements	1.3	16.9	43.4
JK Lakshmi Cem.	0.6	2.6	1.1
The Ramco Cement	0.6	8.6	22.4
Shree Cement	-0.3	-1.8	7.7
UltraTech Cem.	-0.9	-3.7	0.4
Consumer		-3.7 -3.2	- <b>4.5</b>
	- <b>1.0</b> -0.2	- <b>3.2</b> -4.7	-23.9
Asian Paints Britannia Inds.			
	-1.5	-8.8	3.5 -19.2
Colgate-Palm.			
Dabur India	-1.4	-1.5	-23.5
Emami Godrai Consumar	-0.6	-7.7	-18.9
Godrej Consumer	-1.3	-6.1	-15.6
Hind. Unilever	-0.6	-1.7	-6.8
ITC	-1.7	-3.3	1.7

Company	1 Day (%)	1M (%)	12M (%)
Indigo Paints	-2.3	10.1	-20.4
Jyothy Lab.	-2.0	0.3	-23.5
L T Foods			
	-1.1 -0.2	23.9	78.6
Marico		-5.0	13.1
Nestle India	-0.4	0.3	-6.9
Page Industries	-0.2	-0.7	18.9
Pidilite Inds.	-1.1	-2.8	-2.1
P & G Hygiene	0.4	-3.8	-20.4
Radico Khaitan	0.7	0.7	51.1
Tata Consumer	-0.6	-3.6	-2.0
United Breweries	-0.9	0.5	-3.4
United Spirits	-2.2	-6.5	13.9
Varun Beverages	-1.4	-7.6	-25.6
Consumer Durables	-0.5	-2.4	-2.7
Polycab India	-1.0	-3.3	-16.2
R R Kabel	-0.1	7.3	-23.9
Havells	-0.3	0.4	-14.4
Voltas	-0.5	3.4	-22.4
KEI Industries	-1.0	1.6	-13.9
EMS			
Amber Enterp.	-0.9	4.1	59.2
Avalon Tech	1.2	-2.8	59.7
Cyient DLM	-2.1	-1.6	-33.3
Data Pattern	2.5	20.8	9.8
Dixon Technolog.	-1.4	-11.8	31.8
Kaynes Tech	0.0	-12.9	47.1
Syrma SGS Tech.	-1.2	-7.4	12.1
Healthcare	-0.2	2.9	10.8
Ajanta Pharma	-3.5	1.6	8.8
Alembic Pharma	0.5	11.4	13.0
Alkem Lab	0.0	-5.4	-4.8
Apollo Hospitals	0.0	1.1	12.7
Aurobindo	-0.4	-6.0	-8.3
Biocon	0.9	7.7	5.1
Blue Jet Health	-1.1	24.0	143.3
Cipla	0.2	-1.0	-2.5
Divis Lab	-0.9	9.7	45.1
Dr Agarwals Health	0.8	1.3	
Dr Reddy's	0.0	12.9	11.8
ERIS Lifescience	0.2	24.2	75.4
Gland Pharma	1.2	17.9	-9.0
Glenmark	0.1	-4.5	-7.2
Global Health	-2.8	6.6	10.2
Granules	-0.8	18.2	22.0
GSK Pharma	1.8	17.8	36.3
IPCA Labs	-1.1	-2.5	14.1
Laurus Labs	0.0	12.0	51.7
	-1.2	-3.1	
Lupin Mankind Pharma			24.6
Mankind Pharma	2.5	5.2	38.5
Max Healthcare	-0.4	-6.5	6.3
Piramal Pharma	0.1	-6.8	30.5
Sun Pharma	0.0	-0.7	11.7
Torrent Pharma	-0.2	0.5	13.1
Zydus Lifesci.	-0.4	8.1	-10.6





Company	1 Day (%)	1M (%)	12M (%)
Infrastructure	-0.7	1.1	-0.1
G R Infraproject	-1.2	18.1	-20.1
IRB Infra.Devl.	-0.9	4.6	-24.6
KNR Construct.	-0.2	-3.8	-43.6
Logistics			
Adani Ports	-2.8	2.6	0.0
Blue Dart Exp.	-1.6	-8.9	-22.2
Container Corpn.	-1.4	10.5	-33.2
JSW Infrast	-0.6	2.7	4.1
Mahindra Logis.	-1.5	11.4	-26.7
Transport Corp.	-1.2	0.0	21.9
TCI Express	-0.5	9.7	-35.1
VRL Logistics	-0.7	10.3	-5.8
Media	0.2	6.8	-16.1
PVR INOX	-2.9	0.8	-31.4
Sun TV	-1.9	-0.2	-18.4
Zee Ent.	2.1	11.5	-16.8
Metals	-1.0	4.8	-5.9
Hindalco	-1.4	1.1	-5.7
Hind. Zinc	-0.6	19.9	-23.5
JSPL	-2.0	1.2	-11.6
JSW Steel	-0.8	-0.3	7.8
Jindal Stainless	-1.6	14.0	-12.8
Nalco	-0.7	12.5	-0.5
NMDC	-2.8	4.7	-20.4
SAIL	-0.5	11.5	-13.6
Tata Steel	-0.5	1.8	-16.7
Vedanta	-0.5	5.2	4.2
Oil & Gas	-0.6	2.2	-7.8
Aegis Logistics	1.6	17.0	54.9
BPCL	-1.9	16.1	24.3
Castrol India	-1.5	-2.7	-6.0
GAIL	-2.0	1.8	0.8
Gujarat Gas	-0.4	4.1	-13.0
Gujarat St. Pet.	-1.5	3.2	4.5
HPCL	-1.6	1.3	-26.2
IOCL	-0.3	-4.8	8.9
IGL	-1.6	-0.7	9.7
Mahanagar Gas	-1.9	-1.0	-16.9
MRPL	-2.1	-2.2	-18.3
Oil India	-2.7	5.2	-36.1
ONGC	-1.9	-3.4	-8.0
PLNG	2.0	17.3	5.7
Reliance Ind.	1.5	4.3	-9.1
Real Estate	0.1	16.2	-9.1 - <b>10.1</b>
	-2.2		31.4
Anant Raj Brigade Enterpr.	-2.2	18.4 9.7	-13.0
DLF	0.4	25.6	-2.6
Godrej Propert.	0.4	14.3	-20.7
Kolte Patil Dev.	0.8	32.8	-3.8
Mahindra Life.	3.8		
		24.6	-36.8
Macrotech Devel.	0.2	14.0	-5.6 1.5
Oberoi Realty Ltd	0.8	20.1	-1.5
SignatureGlobal	-0.1	10.1	-3.0
Sobha Suntagir Bagitur	-0.9	20.0	-25.6
Sunteck Realty	0.5	10.4	-21.5

Company	1 Day (%)	1M (%)	12M (%)
Phoenix Mills	-0.6	3.7	-7.0
Prestige Estates	1.0	22.9	-11.6
Retail			
Aditya Bir. Fas.	-1.9	-24.4	-38.0
Avenue Super.	-0.5	-0.3	-13.0
Barbeque-Nation	1.8	-2.0	-41.8
Bata India	0.0	0.9	-17.3
Campus Activewe.	-1.2	13.6	-0.6
Devyani Intl.	-1.5	-5.6	-7.9
Go Fashion (I)	-1.0	-4.5	-20.4
Jubilant Food	2.0	-2.9	27.9
Kalyan Jewellers	0.1	-6.4	30.2
Metro Brands	-0.2	6.7	7.8
P N Gadgil Jewe.	1.5	5.8	
Raymond Lifestyl	-2.9	8.5	
Relaxo Footwear	-2.9	-0.1	-49.5
Restaurant Brand	-1.3	-0.8	-26.1
Sapphire Foods	0.3	5.7	6.6
Senco Gold	-1.4	-2.2	-28.0
Shoppers St.	-1.8	-2.1	-32.9
Titan Co.	-0.9	-4.0	-1.5
Trent	-0.7	4.9	11.3
Vedant Fashions	-0.7	6.8	-31.6
V-Mart Retail	-0.4	2.5	29.3
Westlife Food	1.6	2.6	-11.6
Technology	0.0	3.0	10.2
Cyient	-0.8	4.9	-31.6
HCL Tech.	-0.3	4.7	17.4
Hexaware	1.9	11.8	27.1
Infosys	-0.4	2.1	7.2
LTIMindtree	0.3	10.4	7.6
L&T Technology	-1.8	1.8	-9.4
Mphasis	-0.8	6.2	7.6
Coforge	0.4	8.4	70.0
Persistent Sys	-0.7	2.1	55.2
TCS	0.3	-2.0	-11.2
Tech Mah	0.9	5.5	19.4
Wipro	0.2	3.4	7.8
Zensar Tech	0.7	13.1	21.2
Telecom	-0.7	4.1	1.1
Bharti Airtel	-0.2	1.1	29.1
Indus Towers	-0.6	-3.6	12.0
Idea Cellular	-1.6	-3.9	-58.5
Tata Comm	0.1	8.8	-9.3
Utiltites	-0.8	1.8	-14.1
ACME Solar Hold.	0.5	10.9	
Coal India	-0.4	-1.0	-19.8
Indian Energy Ex	-1.6	-3.9	5.0
JSW Energy	-1.9	6.9	-23.1
NTPC	-0.5	-2.8	-10.3
Power Grid Corpn	-1.2	-4.3	-10.3
Suzlon Energy	-1.4	12.4	29.8
Tata Power Co.	-1.4	2.1	-12.1
Others	<u> </u>	۲.۲	12.1
APL Apollo Tubes	-0.9	-3.7	-6.8
Cello World	0.5	7.0	19.9
CCIIO VVOITU	0.5	7.0	19.5





Company	1 Day (%)	1M (%)	12M (%)
Coromandel Intl	2.0	8.4	14.1
Dreamfolks Servi	0.9	25.4	57.9
EPL Ltd	1.6	1.4	-8.3
Eternal Ltd	-1.0	7.5	34.7
Godrej Agrovet	1.5	4.8	26.2
Gravita India	1.9	8.1	33.0
Havells	-0.3	0.4	-14.4
Indiamart Inter.	-1.2	10.5	24.3
Indian Hotels	-1.0	5.0	-4.0
Info Edge	-0.2	2.4	26.8
Interglobe	-0.6	-0.3	16.5
Kajaria Ceramics	-3.9	-4.7	22.3
emon Tree Hotel	-3.4	7.4	280.8
MTAR Technologie	0.6	-0.2	-4.2
One 97	-1.5	3.1	106.1
Piramal Enterp.	-1.8	5.3	28.6
Quess Corp	0.8	-14.1	3.1
SIS	0.4	12.1	-15.9
Swiggy	-0.5	14.1	
Time Technoplast	1.3	31.2	43.0
Team Lease Serv.	-1.2	-0.4	-32.1
Updater Services	-0.2	0.1	0.5
UPL	0.0	-1.6	18.2
Voltas	-0.5	3.4	-22.4

Investment in securities market are subject to market risks. Read all the related documents carefully before investing



#### NOTES



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

<sup>\*</sup>In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motila

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <a href="https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx">https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx</a>

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) d)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Disclosure of Interest Statement Companies where there is interest Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act 1934 act 1934) and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under



applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

#### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.